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ABSTRACT 
 
 
Proline-Rich Transmembrane Protein 2 (PRRT2) has been identified as the 
single causative gene for a group of paroxysmal syndromes, including 
benign familial infantile seizures, paroxysmal kinesigenic dyskinesia and 
migraine. Most of the mutations of this gene lead to a premature stop 
codon, generating an unstable form of mRNA or a truncated protein that is 
degraded, pointing out the loss of the PRRT2 function as pathogenic 
mechanism of action. In this thesis, we have used different approaches to 
investigate the pathophysiological function of PRRT2. An important role for 
PRRT2 in the neurotransmitter release machinery, brain development and 
synapse formation has been uncovered by a previous work performed in 
our laboratory by acute silencing of PRRT2 expression. Here, we analyzed 
the phenotype of primary hippocampal neurons obtained from mouse 
PRRT2 knockout (KO) embryos. Analysis of synaptic function in primary 
neurons obtained from PRRT2-KO showed a largely similar, albeit 
attenuated, synaptic phenotype with respect to acute PRRT2 silencing 
characterized by weakened spontaneous/evoked synaptic transmission and 
increased facilitation at excitatory synapses. These effects were 
accompanied by a strengthened inhibitory transmission that, however, 
displayed faster synaptic depression. At the network level, these synaptic 
phenotypes, resulted in a state of increased spontaneous and evoked 
neurotransmitter release with increased excitability of excitatory neurons. 
To better dissect the physiological role of PRRT2, we characterized the 
phenotypes of neurons differentiated from Induced Pluripotent Stem Cells 
(iPSCs) from patients homozygous for the PRRT2 c.649dupC mutation. 
Hence, we observed an increased Na+ current and firing activity in iPSCs 
rescued with the re-expression of the human wild-type form of PRRT2. By 
use of heterologous expression system, we demonstrate that PRRT2 
interacts with NaV1.2/NaV1.6, but not with NaV1.1 channels, modulating 
their membrane exposure and decreasing their conductances.  
In brief, our findings highlighted that PRRT2 mutations might be a negative 
modulator of NaV1.2/NaV1.6 channels and point out the critical role of this 
protein in the regulation of the neuronal network functionality.  
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1. INTRODUCTION 
 
 
1.1. The Paroxysmal Disorders 
 
Paroxysmal Disorders (PDs) represent a heterogeneous group of rare 
neurological disorders sharing similar features, such as abnormal 
movements, dystonia, chorea, athetosis and ballism, or a combination of all 
these disorders (Bhatia, 2011). These pathological conditions are often 
associated with epilepsy (Fig. 1). PDs usually begin during childhood and 
tend to improve with age (McGrath and Dure, 2003). They are generally 
characterized by episodic nature and by short duration of the attacks 
(Unterberger and Trinka, 2008). 
Shuzo Kure clinically reported PD for the first time in 1892 in a 23-year-old 
Japanese man who showed frequent movement-induced paroxysmal 
attacks from the age of ten (Kure, 1892). In 1995, Demirkiran and Jankovic 
proposed a classification of PDs based on precipitating events and 
differentiated four main types of PDs: Paroxysmal Kinesigenic Dyskinesia 
(PKD), Paroxysmal Non-Kinesigenic Dyskinesia (PNKD), Paroxysmal 
Exercise-Induced Dyskinesia (PED) and Paroxysmal Hypnogenic 
Dyskinesia (PHD) (Demirkiran and Jankovic, 1995). A subsequent 
classification of PDs was based on the duration of the attacks and on the 
presumed etiology. By this, the PDs was classified as primary (familial or 
sporadic) and secondary (Unterberger and Trinka, 2008).  
In the first time, primary PD-related disorders were hypothesized to be ion 
channels-related dysfunctions, indicated with the generical name of 
“channelopathies” (Bhatia, 2000). This hypothesis was corroborated from 
the discovery of mutations occurred in genes encoding for ion channels 
(Fink et al., 1996; Fouad et al., 1996; Bhatia, 2000). Moreover, it was 
observed a sensitivity of some subtypes of PDs to anticonvulsant drugs at 
low dose to modulate the conductance of several ion channels (Bhatia, 
2000, Erro et al., 2014). 
Recently, several studies reported three major PD-related genes: 
Myofibrillogenesis regulator 1 (MR-1) (Raskind et al., 1998; Lee et al., 
2004), Glucose Transporter 1 (SLC2A1) (Wang et al., 2000; Vermeer et al., 
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2007) and the Proline-Rich Transmembrane Protein 2 (PRRT2) (Chen et 
al., 2011).  
Human MR-1 is located on human chromosome 2q35 and has three 
isomeric forms: MR-1L, MR-1M and MR-1S, formed by alternative splicing 
(Lee et al., 2004). Mutations in the N-terminal region of MR-1L and MR-1S 
are the main causes of PNKD: for this reason, the gene is also known as 
PNKD (Lee et al., 2004, Wang et al., 2017a). In a previous study, it was 
found that MR-1 gene is homologous to the hydroxyacylglutathione 
hydrolase gene (Lee et al., 2004). Because this gene functions in a 
pathway to detoxify methylglyoxal, a by-product of oxidative stress present 
in coffee and alcoholic beverages (Wang et al., 2011), it was suggested a 
mechanism whereby alcohol, coffee and stress may act as precipitants of 
attacks in PKND (Lee et al., 2004). 
Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1), 
also known as GLUT1, encodes for the D-glucose transporter across the 
blood brain barrier, GLUT1 protein (Wang et al., 2000). Numerous studies 
have demonstrated that different mutations in SLC2A1 might be important 
to lead PED without epilepsy or co-occurrence of PED with epilepsy (Suls 
et al., 2008). Moreover, Wang et al. (2016) screened MR-1 and 
SLC2A1 genes in 28 patients who were diagnosed with sporadic PKD but 
not carrying PRRT2 mutations. 
Until now, PRRT2 is the major gene accounted for PKD (frequency of 40-
90%) (Chen et al., 2011), for Benign Familial Infantile Epilepsy (BFIE) 
(80%) and for Infantile Convulsion and Choreoathetosis (ICCA) (>90%) 
(Heron et al., 2012; Marini et al., 2012).  
Recent findings associate PRRT2 functions also at presynaptic level (Liu et 
al., 2016; Valente et al., 2016a), and this data added that PRRT2-related 
disorders can be considered synaptopathies too (Erro et al., 2014).  
The broad spectrum of clinical manifestations suggests that there is a 
marked pleiotropy and variable penetrance of PRRT2 mutations (Erro et al., 
2014).  
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Figure 1. Clinical Spectrum of PRRT2 Mutations Disorders. The large yellow 
arrow indicates the most common phenotypes caused by PRRT2 mutations: 
paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), 
infantile convulsions with choreoathetosis syndrome (ICCA). The thin orange and 
brown arrows point to the less frequent clinical spectrum of disorders produced by 
PRRT2 mutations: paroxysmal non-kinesigenic dyskinesia (PNKD), paroxysmal 
exercise-induced dyskinesia (PED), paroxysmal hypnogenic dyskinesia (PHD), 
febrile seizures (FS), episodic ataxia (EA) and hemiplegic migraine (HM) and 
intellectual disability (ID). The dashed blue arrow indicates the other hypothetical, 
but at now unverified, clinical manifestations induced by PRRT2 mutations (From 
Méneret et al., 2013, modified). 
 
 
1.2. The PRRT2 gene 
 
Over the past five years, numerous studies have identified nonsense, 
frameshift and missense mutations in the PRRT2 gene in a large number of 
patients with various paroxysmal neurological disorders with early-onset 
manifestations (Chen et al., 2011; Lee et al., 2012).  
The PRRT2 gene (Entrez Gene: 112476) maps on the short arm of 
chromosome 16 (16p11.2) (Chen et al., 2011) and consists of four exons 
encoding for a 340 amino-acids (AAs) protein. This structure is highly 
conserved among mammals (~80%), with some similarities still appreciable 
in lower vertebrates (~30%) (e.g., zebrafish) (Lee et al., 2012). The 
sequence similarity increases in the C-terminal region of the molecule (up 
to 90%) in mammals and 60% in zebrafish (Lee et al., 2012). 
It has been reported that families affected by PKD, BFIE and ICCA showed 
linkage to the large pericentromeric region of chromosome 16 (16p11.2), 
suggesting that these disorders are allelic with variable expressions 
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(Szepetowski et al., 1997; Caraballo et al., 2002). Thus, sequences of more 
than 157 genes in this specific gene region have been sequenced (Kikuchi 
et al., 2007), but a specific gene involved in these pathologies was not 
identified for more than a decade. A large number of PRRT2 mutations 
were identified by the use of the next generation sequencing technique, 
combined with classical linkage analysis (Chen et al., 2011; Wang et al., 
2011). 
A vast majority of PRRT2 mutations reported (about 95%) are nonsense or 
frameshift (Liu et al., 2013). Among these mutations, a common frameshift 
mutation occurs in an unstable region of nine cytosines (c.641-c.649), 
causing the introduction of a stop codon seven AAs downstream of 
insertion (c.649-650insC>p.Arg217Profs*7) (Lee et al., 2012). This mutation 
segregates in about 80% of the PRRT2 mutant families resulting in diverse 
paroxysmal disorders (Ebrahimi-Fakhari et al., 2015). The c.649dupC 
frameshift mutation leads to an unstable mRNA or a truncated form of the 
protein that is degraded, resulting in a loss-of-function pathogenetic 
mechanism (Lee et al., 2012; Li et al., 2015; Liu et al., 2016).  
A variety of other nonsense or frameshift mutations are mostly located in 
the long N-terminal domain of the protein, scattered in the proline-rich 
domain, and only a few involve the transmembrane domains or the 
cytoplasmic loop (Heron et al., 2012). In addition to these truncated 
mutants, a few missense mutations were also identified (Gardiner et al., 
2012). All mutations described so far are depicted in Fig. 2. 
In contrast, other common non-paroxysmal movement disorders, typical in 
many neurodegenerative disorders, such as in Parkinson’s disease, are not 
associated with PRRT2 mutations (Kumar et al., 2012).  
The shared paroxysmal nature of symptoms and genetic findings 
in PRRT2-associated diseases suggested a common pathophysiology that 
involve PRRT2 gene encoding for a protein that it might be important in 
synaptic vesicle (SV) release machinery and in neuronal excitability 
(Ebrahimi-Fakhari et al., 2015).  
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Figure 2. Mapping of PRRT2 mutations superimposed to the domain 
structure of Proline-Rich Transmembrane Protein 2 (PRRT2). Mutations in 
PRRT2 have been recently identified as the cause for a heterogeneous group of 
paroxysmal neurological diseases. The identified nonsense/frameshift and 
missense mutations are reported on the PRRT2 domain structure in the upper and 
lower panels, respectively (from Valtorta et al., 2016). 
 
 
1.2.1. PRRT2 and the Paroxysmal Kinesigenic Dyskinesia 
 
PKD (Online Mendelian Inheritance of Man, OMIM: 128200), together with 
BFIE and ICCA, represents the core of PRRT2-associated disorders (Chen 
et al., 2011; Wang et al., 2011; Heron et al., 2012; Lee et al., 2012; Ono et 
al., 2012). PRRT2 mutations in BFIE and PKD are inherited in an 
autosomal-dominant manner and affect both females and males in 
populations with various ethnic backgrounds (Ebrahimi-Fakhari et al., 
2015). The general clinical features of BFIE-PKD/ICCA will be herein 
discussed.                                                                                                   
PKD is the most frequent of the paroxysmal dyskinesia syndromes but has 
an estimated prevalence of only 1:150,000 in the population (Spacey and 
Adams, 2013). PKD was first described in 1892 in a young Japanese 
patient presenting with short attacks of purposeless involuntary movements 
triggered by rapid voluntary motion, with no loss of consciousness (Kure, 
1892).  
10 
 
Then, Kertesz and colleagues described the phenotypes in 1967 in ten 
patients from six families. The patients showed “short paroxysms of 
unilateral or generalized tonic, choreiform, and athetoid movements that 
were usually precipitated by movement”, suggesting that the disorder was 
often familial and therefore a genetic cause was proposed (Kertesz et al. 
1967). 
Only in 2011, Chen and colleagues showed that the heterozygous 
mutations of the PRRT2 gene at 16p11.2 locus was responsible for PKD 
(Chen et al., 2011). Several independent groups have identified PRRT2 as 
the major causative gene for PKD (Chen et al., 2011; Wang et al., 2011; 
Lee et al., 2012). PKD is often familial with an autosomal-dominant 
inheritance with incomplete penetrance (Lee et al., 2012). Disease 
penetrance is estimated at 60-90% leading to unaffected or only mildly 
affected family members, despite the presence of a known pathogenic 
mutation or a full manifestation (van Vliet et al., 2012). Sporadic PKD cases 
are also reported in different patients carrying the c.649dupC mutation (Li et 
al., 2013). This might be attributed to the incomplete penetrance of 
c.649dupC, or, alternatively, c.649dupC might derive from de novo 
mutations. 
A hotspot mutation c.649dupC has been found in PKD cases from different 
ethnic origins (Méneret et al., 2012; Heron and Dibbens, 2013).     
However, PRRT2 mutations do not account for all PKD cases, especially 
for those sporadic ones, suggesting the existence of additional gene 
mutations or possible misdiagnosis due to overlapping clinical 
manifestations (Lee et al., 2012: Li et al., 2012, Chen et al., 2014). 
Bruno and colleagues proposed diagnostic criteria for PKD in 2004. The 
attacks show an identified kinesigenic trigger, usually lasting for less than a 
minute, with an average ~30 s. Importantly, PKD attacks do not occur 
during sleep and never involve loss of consciousness, pain or weakness. 
The frequency of attacks is variable, usually peaking in puberty, with 
improvement or even remission in adulthood. Auras are frequent, allowing 
in some patients a partial control of the attacks (Bruno et al. 2004; Table 1). 
Diagnostic tests such as Electroencephalography (EEG) and Magnetic 
Resonance Imaging (MRI) do not reveal any distinct abnormalities in PKD 
patients. The few reported interictal studies point to abnormalities in the 
cortico-striatopallido-thalamic circuitry, although the diagnostic and 
pathophysiological implications remain limited (Joo et al., 2005; Zhou et al., 
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2010; Kim et al., 2011, 2014). Notably, the question about the origin of PKD 
attacks (cortical vs. subcortical) remains until now unanswered (Ebrahimi-
Fakhari et al., 2015). 
Different non-specific pharmacological approaches are currently used for 
PKD. Carbamazepine is the drug of choice for PKD. It is used at dosages 
that are much lower than those used to treat epilepsy (e.g. 50-200 mg/day) 
to reduce or to suppress the attacks (Bruno et al., 2004). Other classical 
anticonvulsant agents may also be effective, including phenytoin, valproate, 
oxcarbazepine, lamotrigine, levetiracetam and topiramate (Bruno et al., 
2004; Strzelczyk et al., 2011). 
 
 
 
Table 1. Diagnostic criteria for PKD. Clinical manifestations used to attempt to 
determinate the PKD pathology (From Bruno et al., 2004, modified). 
 
 
1.2.2. PRRT2 and the Benign Familial Infantile Epilepsy 
 
BFIE (OMIM: 605751), once termed benign familial infantile seizures or 
benign familial infantile convulsions, is a self-limiting seizure disorder of 
infancy with autosomal-dominant inheritance (Caraballo et al., 2002). 
Patients have non-febrile seizures with onset between the ages of four and 
twelve months and of age and offset by two years of age (Heron and 
Dibbens, 2013). Neurological tests and imaging studies (EEG and MRI) are 
usually normal. This syndrome was originally defined from Watanabe and 
colleagues in 1987 (Watabe et al., 1987). The phenotype was described in 
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depth in 1992 and named ‘benign familial infantile convulsions’ (Vigevano 
et al., 1992). BFIE-related seizures usually occur in clusters of complex-
partial or generalized tonic-clonic seizures, and in this context, motor arrest, 
decreased responsiveness, and automatisms, were reported (Watanabe et 
al., 1987). Watanabe and colleagues observed that the infants showed an 
apparently normal developmental outcome and that seizures were easily 
controlled with antiepileptic drugs (Watanabe et al., 1987), which is in 
contrast to what happen in many cases of seizures during infancy (Heron 
and Dibbens, 2013). Vigevano and colleagues (1992) described other BFIE 
diagnostic cases in which the epilepsy was familial showing a favourable 
outcome. Moreover, these patients presented clinical features similar to 
those seen in benign familial neonatal convulsions, apart from the age of 
onset (Vigevano et al., 1992). It was also observed that the features in 
these patients overlapped those described by Watanabe in 1987. The 
therapy with drugs such as phenobarbital, carbamazepine or valproate has 
been frequently used, and generally, a combination of two or more 
anticonvulsants was not employed (Caraballo et al., 2002). In addition, 
seizures often remit shortly after the start of anticonvulsants but, because of 
the benign course of the syndrome and the spontaneous remission of 
seizures, patients with low seizure frequency do not necessarily have to be 
treated (Callenbah et al., 2002). So it is very important that mutations in 
PRRT2 have been identified in the majority of families with BFIE, resulting 
in 602 patients with PRRT2-associated BFIE reported to date (Ebrahimi-
Fakhari et al., 2015). 
 
 
1.2.3. PRRT2 and the Infantile Convulsion and Choreoathetosis  
 
ICCA (OMIM: 602066) is a syndrome in which BFIE and PKD co-occur in 
the same patient or family as a single autosomal dominant trait (Heron et 
al., 2012, Lee et al., 2012). In 1997, Szepetowski and colleagues identified 
four French families in which BFIE was inherited as an autosomal dominant 
trait together with variably expressed paroxysmal choreoathetosis 
(Szepetowski et al., 1997). The strong association of both neurological 
symptoms in the same families defined ICCA as a new syndrome, which 
can be distinguished as a separate entity, although its convulsive 
component is similar to the one initially described by Vigevano et al. (1992). 
13 
 
In these families the locus of ICCA overlapped with the first locus of PKD 
on chromosome 16. Moreover, additional families with ICCA and linkage to 
the same region were characterized (Swoboda et al., 2000). To date, more 
than 200 PKD/IC patients with PRRT2 mutations have been reported 
(Cloarec et al., 2012). 
In conclusion, BFIE, PKD and ICCA form a continuous disease spectrum 
and the core of PRRT2-associated diseases. The natural evolution from 
infantile seizures to a paroxysmal movement disorder in adolescents is 
peculiar. However, both ends of the spectrum share many key features, 
namely their paroxysmal and stereotypical character, benign nature, 
excellent response to anticonvulsants and favourable prognosis (Ebrahimi-
Fakhari et al., 2015). 
 
 
1.2.4. PRRT2 and the Intellectual Disability 
 
Despite is known a large number of mutations of PRRT2 gene, a fine 
correlation between genotype and phenotype is missing until now (Lee et 
al., 2012). 
Heterozygous PRRT2 mutations are mainly reported as loss-of-function 
mutations (Dale et al., 2012) in BFIE, ICCA, or PKD, which share a self-
limited disorder and good prognosis (Labate et al., 2012). In 2011, an 
Iranian family with five individuals with severe non-syndromic ID was 
described, carrying a homozygous mutation in the PRRT2 gene 
(c.649dupC) (Najmabadi et al., 2011).  
Labate and colleagues in 2012 described few patients carrying 
homozygous mutations (Labate et al., 2012) and then other fifteen patients 
with homozygous or compound-heterozygous mutations have been 
reported (Najmabadi et al., 2011; Liu et al., 2013; Chen et al., 2014; 
Delcourt et al., 2015). The patients showed a more severe encephalopathic 
phenotype, including cognitive and neurological development deficit in 
addition to the common paroxysmal movement disorder (Labate et al., 
2012). A great variability within PRRT2-linked phenotypes was shown even 
within the same family. In this context, the members of the family with 
mutation, showed febrile convulsion, epileptic seizures, PKD or headache 
(Brueckner et al., 2014). These pleiotropic effects probably suggest the 
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presence of additional genetic or acquired factors, which modulate the 
clinical expression of PRRT2 mutations. 
Because the c.649dupC mutation introduces a premature stop codon that 
causes truncated polypeptide lacking a transmembrane domain, it is 
probable that homozygous mutations demolish any binding ability with 
interactive proteins or ligands such as Synaptosomal-Associated Protein 25 
kDa (SNAP-25), and could well explain the very severe phenotype, in 
particular the mental retardation (Labate et al., 2012). 
In conclusion, the association of PRRT2-linked pathologies with the more 
severe phenotype of homozygous mutations indicate that the disorders are 
attributable to loss-of-function of the protein and the existence of a gene-
dosage effects (Ebrahimi-Fakhari et al., 2015; Michetti et al., 2017). This 
further highlights the importance of PRRT2 for synaptic functions and might 
suggest an additional role during neuronal development. 
15 
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Table 2. Reported compound-heterozygous and homozygous PRRT2 
mutations (number PRRT2 mutations= 15). ADHD (attention-deficit hyperactivity 
disorder); DD (developmental delay); ID (intellectual disability) (Ebrahimi-Fakhari et 
al., 2015, modified). 
 
 
1.3. The full-length PRRT2 protein and its role until now  
 
The predicted structure of the PRRT2 protein contains a proline-rich 
domain within N-terminal region and two putative transmembrane domains 
divided by few AAs that anchor the protein to the plasma membrane (Chen 
et al., 2011; Méneret et al., 2012; Heron and Dibbens, 2013). Owing to this 
general structure, PRRT2 was assigned to the recently characterized family 
of dispanins (DSPs) (Sӓllman et al., 2012), which share the two-
transmembrane domains topology. DSPs putative topology is characterized 
by two transmembrane helices in the C-terminal region of 20-30 AAs, 
separated by an intracellular loop of variable length, an often long N-
terminal region (>10 AAs), both of which are oriented towards the 
extracellular space (Sӓllman et al., 2012).  According to this topology, it was 
suggested that the long PRRT2 N-terminal domain could be oriented 
outside of the cells, interacting with proteins of the extracellular matrix 
and/or to the extracellular domains of synaptic proteins, hence working as a 
synaptic adhesion molecule (Rossi et al., 2016). The crucial role of several 
trans-synaptic interacting proteins in synapse formation, and they role in 
pathologies that cause synaptopathies when mutated, has been envisaged 
in epilepsy and/or autism (Südhof, 2008; Cowell, 2014). The predicted 
primary structure of human PRRT2 identified two transmembrane helices in 
the C-terminal region of the protein (TM1: AAs 269-289, exon 1; TM2: AAs 
318-338, exon 2): a long and putatively N-terminal region (AAs 1-268), 
including a proline-rich domain (AAs 131-216) and an intracellular loop 
(AAs 290-317) connecting the two transmembrane helices and a very short 
C-terminal end (Rossi et al., 2016). The mouse PRRT2 ortholog is virtually 
identical to the human protein in the C-terminus, with few differences in the 
N-terminal region (Chen et al., 2011) (Fig. 3 A). 
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Figure 3. The gene, the protein structure and the putative membrane 
topology of PRRT2. A. the PRRT2 gene contains four exons (1-4) encoding a 
protein of 340 AAs. Protein domains are highlighted: TM1 (269-289) and TM2 (318-
338) domains, the long N-terminal domain (1-268) containing a proline-rich region 
(PRD), an intracellular loop (CYT, 290-317) and a COOH-terminal dipeptide (339-
340). B. membrane topology hypothesized for PRRT2, member of the Dispanin 
family (DSP) (Chen et al. 2011; Sallman-Almen et al., 2012, modified). 
 
 
However, different structural features were obtained when the orientation of 
PRRT2 in the plasma membrane was investigated experimentally. A recent 
study conducted in our laboratory, revealed, in fact, that the large N-
terminal domain was located in the cytosol, and the very short C-terminus 
in the extracellular side of the plasma membrane (Ncyt/Cexo orientation) 
(Rossi et al., 2016) (Fig. 3 B). This topology resembles that of type 2 
transmembrane proteins with a very short C-terminal anchor and suggests 
that the second C-terminal hydrophobic stretch spans the plasma 
membrane, the first one is associated with the inner surface of the 
membrane without crossing it (Rossi et al., 2016). This important evidence 
introduces the hypothesis of a new set of putative protein interactors for 
PRRT2, with different functions, respect to the previous hypothesized 
structure. In our laboratory we have recently demonstrated that PRRT2 
interacts with a few SH3 domains proteins, specific synaptic and regulatory 
proteins involved in exo/endocytosis of SVs or in signal transduction (Rossi 
et al., 2016). A previous work described that PRRT2 binds Intersectin 1 
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(involved in clathrin-mediated endocytosis at nerve terminals, Saheki and 
De Camilli, 2012), proving the intracellular localization of the N-terminus 
and its function related to SVs homeostasis. This interaction suggests a 
direct important role of PRRT2 in the regulation of vesicle trafficking and 
endocytosis (Rossi et al., 2016). 
Many studies showed that PRRT2 presents a neuron-specific expression, 
detecting the highest levels of mRNA of the protein in the cerebellum, basal 
ganglia and neocortex in humans and rodents (Fig. 4 A) (Chen et al., 2011; 
Heron et al., 2012; Lee et al., 2012, Valente et al., 2016a; Michetti et al., 
2017). Notably, all these regions are putatively involved in the pathogenesis 
of the PRRT2-linked diseases.  
PRRT2 mRNA levels are regulated during development in mouse brain: 
they increase during neural development from postnatal (P) day P0 to P14 
and then they are regulated negatively in adulthood (Chen et al., 2011). 
This evidence reflects probably the observation that in many cases PRRT2-
dependent diseases in infancy are relatively benign and generally are 
attenuated in the adulthood (Chen et al., 2011). Longitudinal analysis of the 
murine nervous system revealed low levels of both PRRT2 mRNA and 
protein during early development, with marked increases postnatally (Chen 
et al., 2011; Ebrahimi-Fakhari et al., 2015; Valente et al., 2016a). A 
previous study from our laboratory has shown that, in primary cultures of 
cortical neurons and hippocampal neurons, PRRT2 was already expressed 
at early postnatal stages, and its expression increased reaching a plateau 
at one month of life (10-21 days in vitro, DIV), a period of intense synapse 
formation and rearrangement in vitro (Valente et al., 2016a) (Fig. 4 B). 
Of note, PRRT2 expression was almost undetectable in primary astroglial 
cultures, showing its neuron-specific expression (Valente et al., 2016a). 
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Figure 4. The PRRT2 neuronal expression and its enrichment at presynaptic 
level. A. Regional expression of PRRT2 in the mouse brain. Western blot analysis 
of PRRT2 protein levels in mouse brain regions at embryonic (E14) and postnatal 
(P60) stages of development. Brain, Total brain; Ob, Olfactory bulb; PFCx, 
Prefrontal cortex; MCx, Motor cortex; SCx, Somatosensory cortex; Str, Striatum, 
Hip, Hippocampus; Cb, Cerebellum, Bs, Brain stem. GAPDH was used as loading 
control. B. Temporal expression profile of PRRT2 in the developing mouse brain 
and in primary hippocampal neurons. C. Ultrafractionation of brain synaptosomes. 
Purified synaptosomes from adult mouse brain were subjected to ultrasynaptic 
fractionation to separate the active zone (AZ), postsynaptic density (PSD), and 
non-synaptic synaptosomal density (NSSP) made by extrinsic and integral 
membrane proteins of the nerve terminal. Aliquots of total synaptosomes and of 
each ultrasynaptic fraction were probed with antibodies against PRRT2, SNAP-25, 
and protein markers to validate ultrasynaptic compartments such as 
Synaptophysin-1 (Syp1) and Post-synaptic Density 95 (PSD95, 95 kDa), a post-
synaptic marker for glutamatergic synapses. The partition of PSD95, Syp1, and 
SNAP-25 in the corresponding fractions is shown. Note that PRRT2 preferentially 
partitioned in the NSSP fraction, similarly to Syp1 and SNAP-25. D. Subcellular 
distribution of endogenous PRRT2 in neurons. Forebrain fractions obtained at 
various stages of SV purification were analysed by western blotting using 
antibodies to PRRT2, SNAP-25, and Syp1. H, homogenate; S1, post-nuclear 
supernatant; S2, supernatant of P2; P2, crude synaptosomes; LP1, crude synaptic 
plasma membranes; LS1, supernatant of LP1; LP2, crude synaptic vesicles; LS2, 
synaptosol; USV, highly purified synaptic vesicles; SSV, salt-treated highly purified 
synaptic vesicles; FT, flowthrough fraction containing small presynaptic 
membranes (Valente et al., 2016a, modified).  
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In neurons, like other proteins codified by genes involved in epilepsy 
(Syntaxin-Binding Protein 1, Dynamin 1 and Leucine-Rich Glioma 
Inactivated 1 genes), PRRT2 shows a distal distribution at synapses. At this 
level, PRRT2 is co-distributes with other proteins associated with the 
presynaptic site (Lee et al., 2012; Liu et al., 2016; Valente et al., 2016a). 
By use of yeast two-hybrid it has been shown a potential interaction 
between PRRT2 and SNAP-25 (Stelzl et al., 2005). SNAP-25 is one of the 
most important soluble N-ethylmaleimide sensitive factor of the SNARE 
(Soluble NSF Attachment Protein Receptor) family, participating in the Ca2+ 
evoked fusion of SVs (Südhof and Rizo, 2011, Lee et al., 2012). This 
interaction was confirmed in a recent work conducted in our laboratory 
(Valente et al., 2016a). We showed that PRRT2 was co-distributed with 
SNAP-25 and with other proteins of the presynaptic site when the brain was 
subjected to subcellular fractionation of the mouse brain (Valente et al., 
2016a) (Fig. 4 C). Interestingly, we also found detectable levels of PRRT2 
in association with SVs (Fig. 4 D), confirming previous proteomic results 
obtained with synaptic fractions enriched in docked SVs (Boyken et al., 
2013). These results corroborate the data that PRRT2 is located at the 
presynaptic site suggesting that during the SVs exo-endocytic cycle, 
PRRT2 cycles between the presynaptic cytoplasm and the SV membranes, 
as shown for SNAP-25 (Walch-Solimena et al., 1995). Although its 
interaction with SNAP-25 may suggest a link with the machinery of 
neurotransmitter release (Lee et al., 2012; Li et al., 2015; Valente et al., 
2016a), the function of PRRT2 is still poorly understood. A high-resolution 
proteomics study revealed the presence of PRRT2 among new auxiliary 
proteins participating in the formation of the AMPA glutamate receptor 
complex, with a preferential association of PRRT2 with the Glutamate 
AMPA receptor subunit 1, GLUA1 (Schwenk et al., 2014). Moreover, low 
levels of PRRT2 are also detected in fractions of proteins of post-synaptic 
densities (Liu et al., 2016; Valente et al., 2016a). This evidence suggests 
also a postsynaptic localization of PRRT2 and a potential role of this protein 
in the homeostatic control of postsynaptic machinery.  
Because the cytosolic N-domain of PRRT2 accounts for 80% of the primary 
structure of the protein (Chen et al., 2011, Rossi et al., 2016), it opens to 
the possibility of novel interactions of this protein with others cytosolic 
elements involved in presynaptic functions. This possibility was explored 
and corroborated by Valente et al. (2016a), demonstrating an important 
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physiological role for PRRT2 in the regulation of the Ca2+-sensing and SVs 
fusion machinery. In that study it was demonstrated that PRRT2 interacts 
not only with SNAP-25, but also with Vesicle-Associated Membrane Protein 
2 (VAMP-2), a member of the vesicle-associated membrane protein 
VAMP/synaptobrevin family and with two forms of synaptotagmin, 
Synaptotagmin 1 and Synaptotagmin 2 (Syt1/2) (see Fig. 5). Notably, all 
these proteins are intimately implicated in the Ca2+-sensing mechanism 
involved in the final steps of fast synchronous neurotransmitter release (Lee 
et al., 2012; Boyken et al., 2013; Valente et al., 2016a). 
It was shown that the reduced PRRT2 expression in hippocampal primary 
neurons led to an abnormal asynchronous/synchronous neurotransmitter 
release ratio suggesting that the fusion mechanism per se is not altered 
and that a specific defect in coupling Ca2+ influx to exocytosis may be 
involved (Valente et al., 2016a). Interestingly, a previous study reported 
similar results in a mouse strain carrying a Syt2 mutation and manifesting 
with EA (Pang et al., 2006a), one of the clinical phenotypes of PRRT2 in 
humans.  
Finally, in the study of Valente et al. (2016) it was found that PRRT2 acute 
silencing caused a diminution of synaptic contacts, and minor changes in 
synaptic ultrastructure consisting of a small reduction in the SV volume and 
an increase in the fraction of SVs docked at the release sites (Valente et 
al., 2016a). A similar study, using RNA interference, showed that knocking 
down PRRT2 expression in mouse embryos led to a delay in neuronal 
migration and defects in synaptic development (Liu et al., 2016).  
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Figure 5. The PRRT2 protein is a key factor of SNARE complex. A. 3D 
reconstruction of the ultrastructure of a presynaptic terminal from serial sections. B. 
Cartoon of the presynaptic portion of the nerve terminal located at the active zone. 
PRRT2, associated with the presynaptic plasma membrane, interacts with the 
other proteins of the SNARE complex (SNAP-25 and VAMP/synaptobrevin) and 
with the fast Ca2+ sensor synaptotagmin. Presynaptic Ca2+ channels and Ca2+ ions 
are also represented. C. Mechanistic model for the role of PRRT2 in Ca2+-
dependent fast SV release. At rest (left), PRRT2 is in the proximity of both the Ca2+ 
sensor synaptotagmin and the SNARE complex; upon stimulation (right), after 
increase of concentration of Ca2+ ions, PRRT2 interacts with both SNARE proteins 
and synaptotagmin. As a consequence PRRT2 endows the SNARE complex with 
Ca2+-sensitivity and increases the probability of synchronous neurotransmitter 
release (from Valtorta et al., 2016). 
 
 
In order to deeply investigate the role of PRRT2 at synapses, it has been 
recently characterized in our laboratory a genetically altered mouse in 
which the PRRT2 gene has been constitutively inactivated (PRRT2-KO). In 
agreement with the previous report, the expression of PRRT2 protein in 
various brain area was confirmed (Michetti et al., 2017).  
The PRRT2-KO mice were normal at birth and their viability was not 
impaired by PRRT2 inactivation. The general health status of PRRT2-KO 
pups were comparable to that of heterozygous and wild-type animals 
(Michetti et al., 2017).  
The PRRT2-KO mice showed a higher frequency of abnormal events than 
heterozygous and wild-type mice starting from P8, a crucial window for 
movement development. In particular, PRRT2-KO mice presented loss of 
equilibrium at P8, with completely balance impairments at P16. 
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Furthermore, PRRT2-KO mice showed bouncing and back walking 
movements, demonstrating paroxysmal behaviours (Michetti et al., 2017). 
These motor alterations were accompanied by paroxysmal dyskinesias 
(increase of frequency of racing and jumping) in response to audiogenic 
stimulations. Pharmacologically, the PRRT2-KO mice exhibited an increase 
of susceptibility to the effects of convulsant drug propentylentetrazole 
(Michetti et al., 2017). 
This phenotype persisted in the adult PRRT2-KO mice and is similar to the 
phenotype of patients with EA type 1 described by Graves et al. (2014), 
suffering of brief attacks of unsteadiness and dizziness with persistent 
myokymia (Graves et al., 2014). 
Electrophysiological data from granule cells of the dentate gyrus of the 
hippocampus showed that synaptic transmission was not markedly altered, 
except for an increase in miniature excitatory postsynaptic currents 
(mEPSCs), a result consistent with the increased density of VGLUT1-
positive synapses described from Michetti et al. (2017). In the cerebellum, 
functional analysis showed a long-lasting facilitation at the synapses of 
parallel fiber-Purkinjie cells synapses while no evident depression was 
observed, even at the highest stimulation frequency (Michetti et al., 2017). 
An altered plasticity, together with a sharp decrease of evoked synchronous 
transmission, probably due to a loss of Ca2+ sensitivity of the release 
machinery, suggested that the absence of PRRT2 induces functional 
abnormalities due to a global network instability and/or excitation/inhibition 
imbalance (Michetti et al., 2017). 
Furthermore, homozygous PRRT2-KO mouse recapitulated many of the 
phenotypic features of the human PRRT2-linked disorders, showing 
abnormal motor behaviors and a motor/epileptic phenotype in response to 
environmental stimuli. By contrast, the heterozygous mice did not show any 
evidence of pathogenic phenotype (Michetti et al., 2017). 
In a recent work it was demonstrated a direct evidence between PRRT2-
associated dyskinesia and specific cerebellar presynaptic deficits (Tan et 
al., 2017). In that study mutant mice with global or cerebellum-specific 
truncation exhibited severe episodes of aberrant motor behaviours similar 
to the clinical features of PKD in patients, including dyskinesia and 
dystonic postures. These manifestations have been confirmed by 
electron microscopic and electrophysiological analyses of the cerebellar 
to Purkinje cell inputs. Mutant mice in which PRRT2 was deleted in 
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granule cells of the cerebellum exhibited a facilitated transmission at 
parallel fiber-Purkinjie cells synapses, showing an enhanced firing of 
Purkinjie cells and a typical paroxysmal behavior (Tan et al., 2017).  
 
 
1.4. Neurological Paroxysmal Disorders and ion channels 
 
Ion channels are the most fundamental elements in excitability of the 
membrane of cells and are expressed broadly throughout the body (Hille, 
2001). Mutations of ion channels in central nervous system (CNS) underlie 
a broad spectrum of episodic neurological disorders. In this context, PDs 
and other episodic movement disorders are often proposed to be 
channelopathies (Bhatia et al., 2000; Margari et al., 2005; Ryan and Ptácek 
et al., 2010). Here we schematically analyse channelopathies related to 
different voltage-gated ion channels dysfunctions that are involved in a 
variety of paroxysmal-like seizures. The major inherited diseases of 
different voltage-gated ion channels are reported in Table 3. 
The Voltage-gated K+ Channels (KV) belongs to the large family of proteins 
composed by six transmembrane α helices (S1-S6), with S4 subunit 
serving as the voltage sensor and a pore-forming loop between S5 and S6 
subunits. Moreover, four of such subunits constitute a functional channel 
(Gutman et al., 2005). KV channels are largely activated during the 
repolarizing phase of the membrane after the depolarization phase mediate 
by Na+ and Ca2+ influx (Liu and Bean, 2014). 
KV channels Kv7.2 and Kv7.3, encoding by K+ Voltage-gated Channel 
Subfamily Q Member 2 (KCNQ2) and K+ Voltage-gated Channel Subfamily 
Q Member 3 (KCNQ3) genes, have an important role in limiting network 
excitability in the neonatal brain (Rogawski et al., 2000). KCNQ2 and 
KCNQ3 mutations were found in families with different neurological 
disorders, such as self-limited epilepsy and/or BFIE (Maljevic and Lerche, 
2014). 
In 2009, an autosomal recessive disorder characterized by the tetrad of 
Epilepsy, Ataxia, Sensorineural deafness, and Tubulopathy (a renal salt-
wasting), defined EAST syndrome, was firstly described by two 
independent groups (Bockenhauer et al., 2009; Scholl et al., 2009). This 
syndrome is caused by loss-of-function mutations in an inwardly-rectifying 
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K+ channel subtypes 4.1, which has a pivotal role in glial function, neuronal 
excitability, and systemic K+ homeostasis (Scholl et al., 2009). 
Different cases of episodic EA type 1 showed mutations in KCNA1 gene, 
encoding for KV1.1 channels that are expressed in interneurons of the 
cerebellum (Ryan et al., 2010). EA type 1 is inherited in an autosomal 
dominant manner and KV1.1 mutations lead to a drastic decrease in 
currents, often at least partly due to improper trafficking (Ryan et al., 2010; 
D’Adamo, 2015).  
Moreover, several mutations were found in the K+ Ca2+-Activated Channel 
Subfamily M α1 (KCNMA1) gene that encodes for α1 subunit of Ca2+-
activated K+ channels belonging to the family of ion channels with a big 
conductance for K+ ions, named Big K+ channels (Du et al., 2005). These 
channels are involved in neuronal excitability, synaptic transmission and in 
regulation of myogenic tone (Zhang et al., 2015). It was reported a mutation 
in KCNMA1 gene that cause an autosomal dominant form of early onset of 
PNKD (Du et al., 2005). Patients present a non-kinesigenic phenotype with 
alcohol as possible trigger and epileptic attacks (Du et al., 2005). Moreover, 
two PNKD patients with mutations in KCNMA1 gene without epilepsy 
attacks are described (Zhang et al., 2015).  
Voltage-gated Ca2+ channels (CaV) are composed by four or five distinct 
subunits and the α1 represents the largest subunit, incorporating the 
conduction pore and other domains (Catterall et al., 2005a). This subunit is 
organized in four homologous domains (I-IV) with six transmembrane 
segments (S1-S6) in each (Catterall et al., 2005a).  
CaV mediate Ca2+ influx in response to membrane depolarization and 
regulate intracellular processes such as contraction, secretion, 
neurotransmission, and also gene expression in many different cell types 
(Catterall et al., 2005a). The Ca2+ Voltage-gated Channel Subunit A α1 
(CACNA1A) gene encodes for the pore-forming α1 subunit of the P/Q type 
CaV channels, CaV2.1. These channels are highly expressed in cerebellar 
Purkinje cells, in which they mediate neurotransmitter release (Todorov et 
al., 2012). Mutations in CaV2.1 lead to familial HM type 1, EA type 2, and 
spinocerebellar ataxia type 6. Familial HM type 1 mutations cause gain-of-
function effects on these channels, increasing channel activity, synaptic 
transmission, and susceptibility to cortical spreading depression (Tottene et 
al., 2009; Pietrobon, 2010). EA type 2 mutations induce a loss-of-channel 
function, with a decrease in Ca2+ currents through CaV2.1, often due to 
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protein instability (Rajakulendran et al., 2010; Nachbauer et al., 2014). 
Spinocerebellar ataxia type 6 mutations cause a toxic gain-of-function effect 
in which mutant CaV2.1 channels are incompletely degraded forming 
insoluble aggregates and inclusion bodies within Purkinje cells (Unno et al., 
2012). 
Voltage-gated Na+ channels (NaV) are fundamental in the initiation and 
generation of action potentials (APs) in neurons and other excitable cells, 
propagating APs along nerves (axons), muscle fibers and the neuronal 
somato-dendritic compartment (Hille, 2001). NaV are heteromeric 
transmembrane proteins that are open in response to an alterations in 
membrane potential to provide selective permeability for Na+ ions (Anger et 
al., 2001). In mammalian brain are complexes of a 260 kDa α-subunit with 
one or two β-subunits (β1-β4) of 33 to 36-kDa in size (Catterall, 2000; 
Catterall et al., 2005b). The α-subunit consists of four internally repeated 
domains (I-IV), each of which contains six α-helical transmembrane 
segments (S1-S6). In each domain, the S1 through S4 segments serve as 
the voltage-sensing module, and one non-helical relatively short reentrant 
segment, the P-segment, located between S5 and S6, serve as the ion 
selectivity filter and ion pathway (Catterall et al., 2005b; Waszkielewicz et 
al., 2013). Several classical features of NaV described from Hodgkin and 
Huxley defined their functions: a) voltage-dependent activation, b) rapid 
inactivation and c) selective ion conductances (Hodgkin and Huxley, 1952). 
On the other hand, some channels undergo slow-inactivation, which takes 
considerably longer time (seconds to minutes) (Kyle and Ilyin 2007).  
There are ten mammalian α subunit genes encoding the proteins NaV1.1-
NaV1.9 (Namadurai et al., 2015). Separate α subunit isoforms are 
expressed in tissue-specific patterns and exhibit differences in gating 
behaviour that tailor them for distinct physiological roles (Waxman, 2012). 
Among others, the subtypes NaV1.1, NaV1.2 and NaV1.6 are abundantly 
expressed in the CNS and are very important for the integration of 
information at this level (Gordon et al., 1987; Beckh et al., 1989; Vacher et 
al., 2008). In this context, excitatory and inhibitory synaptic inputs are 
integrated in a specific region of the neuron, defined axon initial segment 
(AIS) (Catterall, 1981). The AIS is a proximal part of the axon where Na+ 
channels are grouped and generated the depolarizing phase during an AP. 
The AIS is a specialized structure of about 20-60 μm in neurons that is 
localized between axonal and somatodendritic domains. At this level it 
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operates for the action potential firing and helps to maintain neuron polarity 
(Jones and Svitkina, 2016). 
In excitatory cells, the distal part of the AIS in enriched in NaV1.6 and the 
proximal part in NaV1.2 (Rasband et al., 2010). Functionally, these different 
subdomains of AIS determine the progressive reduction in the half-
activation voltage in the AIS, with increasing distance from the soma (Hu et 
al., 2009). Further molecular model studies supported by simultaneous 
somatic and axonal recordings showed that distal NaV1.6 promotes AP 
initiation, whereas proximal NaV1.2 promotes its backpropagation to the 
soma (Hu et al., 2009). 
On the other hand, recent studies revealed that NaV1.1 is important for the 
excitability of GABAergic neurons clustering in the AIS of some types of 
interneurons (Yu et al., 2006; Ogiwara et al., 2007). Moreover, several 
reports showed that NaV1.1 expressed at somato-dendritic level of neurons 
controls excitability through integration of synaptic impulses regulating the 
threshold for AP generation and propagation to the dendritic and axonal 
compartments (Yu et al., 2006; Vacher et al., 2008).  
The abnormal expression and/or function of NaV channels has been 
investigated in different pathophysiological conditions of the CNS 
(Waszkielewicz et al., 2013).  
In this context, several studies have shown altered levels of mRNA and 
protein for NaV1.1, NaV1.2, NaV1.3 and NaV1.6 α-subunits and for β-
subunits in animal model of epilepsy (Bartolomei et al., 1997; Aronica et al., 
2001; Klein et al., 2004; Blumenfeld et al. 2009) and in human epileptic 
brain tissue (Lombardo et al., 1996; Whitaker et al., 2001). The epileptiform 
activity can also be associated with changes in Na+ channel functions. An 
increase in a small persistent Na+ current due to an incomplete fast 
inactivation of this conductance predisposes neurons to hyperexcitability 
(Crill, 1996; Kearney et al., 2001). 
Thus, in general, diverse mutations in Na+ channels expressed in the CNS 
cause different forms of paroxysmal-related disorders (Erro et al., 2017). A 
heterozygous missense mutation in the neuronal NaV channel gene SCN1A 
(coding for NaV1.1 α-subunit) was identified in families with familial HM with 
aura (Dichgans et al., 2005), one of the several autosomal dominant 
paroxysmal disorders (Marini et al., 2012). Probably, familial HM mutations 
may cause a gain-of-function of the NaV1.1 channels (Scalmani et al., 
2006).  Some mutations in NaV1.1 cause Generalized Epilepsy with Febrile 
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Seizure Plus type 2 and Severe Myoclonic Epilepsy of Infancy (or Dravet 
syndrome) (Catterall et al., 2010; Meisler et al., 2010), revealing a loss-of-
function mechanism. Moreover, several mutations in SCN2A gene (coding 
for NaV1.2 α-subunit) are identified in BFIE (Heron et al., 2002; Scalmani et 
al., 2006), inducing a gain-of-function that leads to paroxysmal 
manifestations. 
Five major phenotypes of SCN2A-benign neonatal infantile, intermediate 
neonatal infantile, severe neonatal infantile, childhood epilepsy, and 
isolated autism and intellectual disability phenotypes are described (Howell 
et al., 2015). Furthermore, it has been recently reported choreoathetosis in 
a child with normal development, de novo SCN2A mutation, and a history of 
neonatal and infantile seizures (George et al., 2017). 
PKD, BFIE, and ICCA have been reported in patients with SCN8A 
mutations (Gardiner et al., 2015; Wang et al., 2017), coding for NaV1.6 α-
subunit.  SCN8A mutations have been identified in three families with a 
total of sixteen affected members, identifying the same cosegregating 
heterozygous missense mutation (Gardella et al., 2016). The paroxysmal 
nature of the clinical symptoms, such as dystonic/dyskinetic or "shivering" 
attacks, triggered by stretching, motor initiation, or emotional stimuli have 
suggested that attacks might in fact be epileptic in nature (Gardella et al., 
2016). Interestingly, other studies on the phenotypic spectrum of SCN8A-
related epileptic encephalopathies reported the presence of choreo-
dystonia and dystonic dyskinesias in some cases (Larsen et al., 2015), 
supporting the idea that episodic movement disorders can occur with 
SCN8A mutations. Furthermore, functional analyses have suggested that 
SCN8A mutations can lead to either gain-of-function (by an increased 
persistent Na+ current) or loss-of-function effects (by an unstable protein) 
(Meisler et al., 2016).  
Different genetic studies have identified the NaV channels NaV1.7 (encoded 
by SCN9A gene) as a key player in several conditions in which recurrent 
pain or the inability to sense pain is the prominent symptom (Yang et al., 
2004; Cox et al., 2006). Recently, a novel p.L1612P NaV1.7 mutation has 
been identified as a cause of paroxysmal extreme pain disorder with a 
unique combination of clinical symptoms and electrophysiological 
properties (Suter et al., 2015). There are several Na+ channel blockers 
used in epilepsy therapy and related pathology, such as phenytoin or 
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carbamazepine that selectively block ion conductance and/or stabilize the 
inactivated state of these channels (Ragsdale et al., 1994, 1996).  
 
30 
 
 
 
 
 
 
31 
 
Table 3. Some significant neurological inherited diseases of voltage-gated 
K+, Ca2+ and Na+ channels at CNS. Several PDs affecting neuronal function and 
ranging in severity (from mild or latent disease to life-threatening or incapacitating 
conditions) have been linked to mutations in different human NaV genes (Gardiner 
et al., 2015, modified). 
 
 
1.5. The Induced Pluripotent Stem Cells Technology 
 
In recent years, researchers have begun to explore the Induced Pluripotent 
Stem Cell (iPSC) technology’s full potential for creating disease models 
from patients with complex genetic defects, thus overcoming major ethical 
concerns that have plagued human embryonic stem cells (ESCs) ESCs 
(Yamanaka, 2010). Before the advent of iPSCs technology, several 
strategies are used to generate such disease models using human ESCs 
(Prajumwongs et al., 2016).  
Human ESCs are pluripotent stem cells derived in vitro from the inner cell 
mass of developing embryos (Gokhale and Andrews, 2006). The first 
human ESCs line was obtained in 1998 from human blastocysts, showing 
the ability to differentiate into ectoderm, mesoderm and endoderm, the 
three germ layers (Thomson et al., 1998). Therefore, human ESC-derived 
cells have been widely used for different analysis such as gene targeting, 
cell therapy, tissue repair, and organ regeneration (Zhao et al., 2013). 
However, the main disadvantages of the use of human ESCs were the 
immune rejection, the incorrect tissue regeneration, the tumor formation, 
and even the ethical considerations about the manipulation of human 
embryos (Isobe et al., 2014; Kim et al., 2014). In 2006, Yamanaka and his 
group opened a completely new venue in stem cell research by showing 
that the forced expression of only four transcription factors was sufficient to 
convert mouse fibroblast cells into ESC-like cells (Takahashi and 
Yamanaka, 2006). These cells, named iPSCs, were considered pluripotent 
stem cells not derived from embryos but from in vitro reprogramming 
methods in order to mimic ESCs (Takahashi and Yamanaka, 2006). Thus, 
iPSCs technology became an extremely useful tool for regenerative 
medicine (Wan et al., 2015) and/or in vitro modelling of disease (Colman et 
al., 2009). A detailed iPSCs scheme generation is reported in Fig. 6. 
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Figure 6. The iPSC technology. Adult somatic cells can be reprogrammed into 
stem cell by the iPSC approach. By the use of this technique, mammalian somatic 
cells were reprogrammed to iPSCs by ectopic expression of the pluripotent factors: 
OCT3/4, SOX2, KLF4, and C-MYC. IPSCs generated in this manner share the 
main properties of preimplantation embryo-derived ESCs, which include unlimited 
self-renewal and the potential to differentiate into cells of the three germ layers. 
IPSC-derived neurons can be obtained from skin biopsies from patients and 
relative healthy controls. IPSCs, owing to their ESC-like pluripotency, allow the 
production of a variety of derived cells such as neurons, for applications in 
regenerative medicine such as transplantation therapy, toxicity tests and also for 
modelling human diseases and new drug development (Wan et al., 2015, 
modified). 
 
 
The growing interest in iPSCs technique and its clinical applications has led 
to the debate about the differences between iPSCs and ESCs, in particular 
if iPSCs are close to the gold standard ESC, and if they are “safe” for 
clinical use (Bilic and Belmonte, 2012).  
The first issue was to understand if the transcriptional profile of good iPSCs 
quality was similar to ESCs (Bilic and Belmonte, 2012). In previous studies, 
iPSCs and ESCs were considered nearly identical to their embryo-derived 
counterparts (Takahashi and Yamanaka, 2006; Maherali et al., 2007; 
Takahashi, 2007; Lowry et al., 2008). Later on, it was demonstrated that a 
small group of genes were continuously differentially expressed in iPSC 
and ESC lines, using genome-wide analysis (Chin et al., 2009). These 
differences were found in early passage iPSC lines, and were conserved 
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across various studies and species, suggesting that the two cell types were 
transcriptionally different (Chin et al., 2010). Moreover, Stadtfeld et al. 
(2010) demonstrated that the expression state of a single imprinted gene 
cluster (Dlk1-Dio3 gene) distinguished most murine iPSCs from ESCs and 
allows for the prospective identification of iPSC clones that have the full 
development potential of ESCs. In human iPSCs, the Dlk1-Dio3 locus is not 
silenced, suggesting a different iPSC state/reprogramming. Thus, it became 
useful to find similar marker in human cells (Bilic and Belmonte, 2012). 
The direct comparison of the differentiation potential of iPSCs and ESC 
presented several difficulties, considering the high variability in the analysis, 
due to different culture conditions and/or differentiation protocols (Bilic and 
Belmonte, 2012). A previous study demonstrated that the human iPSCs 
and ESCs displayed the same neural-differentiation potential, including 
those with or without integrating transgenes (Hu et al., 2010). This indicates 
that techniques other than simple removal of reprogramming transgenes 
are needed to improve the differentiation efficiency and potency for iPSCs 
(Hu et al., 2010).  
The efficiency of differentiation was lower in iPSCs than ESCs, probably for 
epigenetic changes or genetical aberration that occur during the process, 
making iPSCs more refractory to external differentiation signals (Chin et al., 
2009). Importantly, in vitro human ESCs presented various differentiation 
capacity, as some lines showed a marked propensity for differentiating into 
specific lineages, making comparison with iPSCs much more difficult (Hu et 
al., 2010; Osafune et al., 2008).  
Moreover, DNA methylation is an important epigenetic modification of the 
mammalian genome that has widespread influences on gene expression 
(Liu et al, 2008). When analysed, the DNA methylation pattern was very 
similar between iPSC and ESC compared with nonpluripotent lines, such as 
fibroblasts (Guenther et al., 2010). A considerable amount of literature has 
been published on these differentiation properties, using small number of 
iPSC and ESC cell lines for comparison (Doi et al., 2009; Marchetto et al., 
2009; Ghosh et al., 2010; Kim et al., 2011; Lister et al., 2011; Ohi et al., 
2011). Several differentially methylated regions were found comparing 
three iPSC lines and three ESC lines by genome-scale analysis (Doi et al., 
2009). However, the most interesting finding was that not all the 
differentially methylated regions belong to the cell-of-origin memory, 
indicating that iPSCs also accumulate novel aberrant epigenetic state (Doi 
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et al., 2009; Lister et al., 2011). Furthermore, it was found that 
reprogrammed cells re-organize their chromatin architecture to reflect the 
less repressive state of stem cells (Hawkins et al., 2010). Thus, it was 
suggested that inhibiting repressive chromatin structure may facilitate 
reprogramming either through inhibition of the repressive regions or 
overexpression of demethylases. 
Until now, relatively little is known about the differences between ESCs and 
iPSCs about their non-coding regulatory transcripts, such as microRNA 
(miRNA) (Tang, 2005). MiRNA expression profiles are known 
to change depending from the development of tissue and from individual 
cells differentiation (Krützfeldt et al., 2006). Chin et al. (2009) showed that 
there was a difference in the expression profile for 105 miRNAs between 
ESCs, iPSCs and fibroblasts. Moreover, it was demonstrated that few 
miRNA were differentially expressed in both pluripotent cell lines (Chin et 
al., 2009; Wilson et al., 2009). These findings could be explained with the 
variation of miRNA profile during development, suggesting a late iPSCs 
signature (Chin et al., 2009).  
One of the most important discovery relevant for the generation of iPSCs 
was the identification of the key pluripotency molecules, named of 
Yamanaka’s factors (Takahashi and Yamanaka, 2006). Before their 
discovery, other works postulated the existence of factors that could 
change the cellular fate (Davis et al., 1987; Halder et al., 1995; Tada et al., 
2001; Cowan et al., 2005).  
The original method of reprogramming murine fibroblasts by Yamanaka 
utilized retroviral transduction of OCT3/4, SOX2, KLF4 and C-MYC (also 
defined OSKM factors) into mouse embryonic fibroblasts derived from mice. 
These murine fibroblasts expressed β-galactosidase-neomycin fusion 
protein at the Fbx15 locus (Tokuzawa et al., 2003) which is specifically 
expressed in pluripotent stem cells and serves as an excellent marker for 
pluripotency (Takahashi and Yamanaka, 2006). Thus, drug selection with 
G418 after transduction of the OSKM factors resulted in reprogramming of 
0.02% of the mouse embryonic fibroblasts 14-21 days post-transduction 
(Takahashi and Yamanaka, 2006).  
One year later the generation of mouse iPSCs, in Yamanaka’s lab was 
demonstrated that the same OKMS factors were sufficient also to generate 
human iPSCs (Takahashi et al., 2007). Interestingly, the use of only three 
of these factors, omitting C-MYC, was also reported to achieve successful 
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iPSC generation, although with reduced reprogramming efficiency (Wernig 
et al., 2007; Nakagawa et al., 2008). In the same years, another work 
showed the generation of human iPSCs by OCT3/4 and SOX2 factors, the 
same described from Yamanaka’s lab, and two different factors, NANOG 
and LIN28 (Yu et al., 2007). At now, both sets of reprogramming 
compounds are now used. Interestingly, combinations of these two sets 
have a synergistic effect on the generation of human iPSC (Yu et al., 2009; 
Tanabe et al., 2013). 
The use of iPSCs technique is now permeating into many sectors of 
disease research. This approach could be important for several studies of 
brain diseases where the most restrictive limitation is the tissues 
inaccessibility. Reprogramming adult somatic cells from patients into iPSCs 
and then neurons could be important to avoid this problem. In this context, 
patient sample-derived iPSCs can be used to construct patient-specific 
disease models to elucidate previously unknown pathogenic mechanisms 
of disease development and to test new therapeutic strategies (for review, 
see Zhao et al., 2014).  
The procedure of neuronal induction is well described by Broccoli et al. 
(2014; 2015). HPSCs were differentiated into aggregate-like embryoid 
bodies (EBs) and then, the aggregates were growth in a culture medium in 
serum-free condition in order to promote selectively the survival and growth 
of neural cells (Broccoli et al., 2014). Neural rosettes were readily identified 
in the differentiated hPSC colonies as rosette-like structures, while in 
murine-derived cultures the formation of this rosette appeared slower than 
human-derived cells (Reubinoff et al., 2001; Zhang et al., 2001). These 
structures are formed by neural progenitors cells (NPCs), showing a highly 
polarized morphology. Neural rosettes have a structure that morphologically 
resembles the early embryonic neural tube (Zhang et al., 2001). These 
findings suggest that they are equivalent to the developing neural tube with 
respect to structure and function (Broccoli et al., 2014). Rosette neural 
progenitors intertwine to create overlapping cellular layers; however, they 
remain constrained to the surface where they anchor (Broccoli et al., 2014). 
Then, rosette neural progenitors can be expanded in vitro forming a 
renewable cell population as neurospheres in suspension or also attached 
to a substrate. 
NPCs have the ability to generate most neural cell types, such as cortical 
neurons, dopaminergic neurons, GABA-ergic neurons, astrocytes and 
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oligodendrocytes (Begum et al., 2015; Du and Parent, 2015) (see Table 4). 
This is a long and multistep process. At the beginning, neurons show a very 
immature morphology and acquire functional properties only after several 
weeks in culture (Broccoli et al., 2014). To promote a specific neural line, 
different factors of differentiation and growth were added in culture medium 
(Bardy et al., 2015). It was observed that neurons present mature functional 
and synaptic properties after 8-12 weeks in culture (Ricciardi et al., 2012). 
Moreover, some different way to improve neural maturation in vitro are 
described, such as culture supplementation with neurotrophins and cAMP 
that decreases cell death mechanisms (Soldner et al., 2009) and the co-
culture of neurons with primary rat feeder layer (or astrocytes) (Broccoli et 
al., 2014). 
Finally, mature neurons derived from iPSC technology should be 
functionally evaluated by taking into account the electrophysiological 
properties of the newly generated neurons.  
 
 
Table 4. Main neural and other brain-related cell types differentiated from 
iPSCs. The ability to neurally differentiate iPSCs allows one to study the 
development of patient-derived cells over time as they mature and manifest 
neurological disease phenotypes. These “disease-in-a-dish” models provide the 
unique opportunity to understand the progression of pathology and gain insight into 
the prevention of clinical disease onset. (Du and Parent, 2015, modified). 
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2. OBJECTIVES AND APPROACHES 
 
The main purpose of this research project has been to perform a thorough 
investigation of the possible molecular basis of PRRT2-associated 
paroxysmal disorders. The aim of this work was the further characterization 
of the PRRT2 function in the modulation of electrophysiological properties 
of neuronal cells. To this end, we have used different experimental 
approaches. 
First, we have studied the PRRT2-KO mouse model in which the PRRT2 
gene was constitutively inactivated in vitro. We have investigated the 
electrical phenotypes of primary hippocampal neurons, obtained from 
mouse PRRT2-silenced embryos in comparison to WT neurons. The 
functional properties of PRRT2 silenced neurons at single-cell and network 
levels in terms of synaptic properties and excitability have been addressed. 
Second, we generated and characterized iPS cell lines from patients 
carrying a mutated PRRT2, which as allowed to investigate mature human 
neuronal cells as PRRT2-disease model. We have studied IPSCs and 
differentiated into functional neurons that carry the common PRRT2 
mutation c.649dupC. The iPSCs were generated from fibroblasts of patients 
from a consanguineous Italian family carrying the c.649dupC mutation in 
heterozygosity or homozygosity. We used iPSCs generated from sex- and 
age-matched normal donors as controls. All clones generated and 
characterized are summarized in Table 5.  
Finally, we used HEK-293 stably expressing various clones of voltage-
gated sodium channels as model system to deeply investigate the 
modulation of PRRT2 on electrophysiological properties of neuronal cells. 
This study should clarify the functional interactions of PRRT2 with key 
actors of cellular excitability, and address the functional mechanism that 
impairs the normal functionality of the neurons. 
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Table 5. Genotype-phenotype correlation of iPSC clones generated from 
fibroblasts of patients carrying c.649dupC mutation in PRRT2. All clones were 
siblings of a consanguineous Italian family segregating the common PRRT2 
mutation c.649dupC (P1-P3). IPSC clones from two unrelated healthy individuals 
(C1 and C2) were also generated and used as control. For each individual, the 
number of clones (ID) of the respective iPSC clones is reported. 
 
 
3. RESULTS 
 
3.1. Constitutive PRRT2 deletion strongly decreases excitatory 
spontaneous and evoked transmission, strengthening inhibitory 
synaptic transmission  
 
In order to evaluate the functional effects of PRRT2 deletion in vitro, we 
analyzed spontaneous and evoked synaptic transmission in low density and 
autaptic cultures of primary neurons from E18 embryonic hippocampus, 
respectively. Electrophysiological recordings of miniature excitatory 
(mEPSCs) and inhibitory (mIPSCs) postsynaptic currents were performed 
at the soma of voltage-clamped neurons (Vh= -70 mV), plated as low-
density network (Fig. 7 A, B, respectively). Because miniature events 
reflect the spontaneous exocytosis of neurotransmitter-loaded vesicles in 
the absence of APs (Fatt and Katz, 1952), we have conducted the 
electrophysiological recordings in the presence of tetrodotoxin (TTX, 1 μM) 
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in the extracellular solution in order to block spontaneous firing activity. 
Notably, the mEPSCs frequency was significantly lower in PRRT2-KO 
cultures than the frequency recorded in WT hippocampal neurons (Fig. 7 A, 
B, left panels). Statistical analysis of mEPSCs amplitude, kinetics (80% 
decay, rise) and unitary charge (area) was not significantly different from 
WT excitatory control synapses (Fig. 7 C). Conversely, no differences were 
observed in the analysis of mIPSCs parameters studied in PRRT2-KO and 
WT inhibitory synapses (Fig. 7 D). 
We next analyzed evoked synaptic transmission in glutamatergic and 
GABA-ergic hippocampal neurons plated as autaptic cells (Fig.  8 A, B). 
Postsynaptic currents (PSCs) were discriminated for their kinetics and 
sensitivity to the specific blockers of AMPA or GABAA receptors for 
excitatory and inhibitory transmission, respectively (Fig. 8 B). Voltage-
clamp recordings, obtained with paired-pulse stimulation at different 
interpulse intervals (from 20 ms to 10 s, Fig. 8 B, inset), revealed a 
significantly decrease in the amplitude of the first (I1) excitatory evoked 
PSC (eEPSC) in PRRT2-KO condition (Fig. 8 C, left), compared to WT. By 
contrast, we observed a significant increase in the I1 of the inhibitory 
evoked PSC (eIPSC) amplitude (Fig. 8 D, left). The values of paired-pulse 
ratio (PPR) were measured as a function of interstimulus interval (ISI), 
which represent an indirect measure of release probability (Pr) (Fioravante 
and Regher, 2011). PRRT2-KO excitatory synapses showed a two-fold 
increase in paired-pulse facilitation at ISI of 20 and 50 ms, while the 
inhibitory synapses displayed a stronger depression than WT inhibitory 
synapses at the same values ISIs (Fig. 8 C, right and Fig. 8 D, right). 
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Figure 7. PRRT2 deletion decreases spontaneous excitatory transmission. A, 
B. Representative recordings traces of mEPSCs (A) and mIPSCs (B) from WT 
(black) and PRRT2-KO (EPSCs, red; IPSCs, blue) hippocampal low-density 
neuronal networks. C, D. Analysis of mEPSCs (C) and mIPSCs (D). From left to 
right, the mean ±sem values of amplitude, frequency, 10%-90% rise time, 80% 
decay and charge are shown. All parameters were obtained from at least 50-100 
events recorded from WT (n=31) and PRRT2-KO cells (n=34) for mEPSCs and 
from WT (n=25) and PRRT2-KO (n=26) cells for mIPSCs from at least n=3 
independent cell culture preparations. *p < 0.05, unpaired Student’s t-test.  
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Figure 8. PRRT2 deletion decreases evoked excitatory transmission and 
increases evoked inhibitory transmission. A. Phase-contrast micrographs of 
typical glutamatergic (left) and GABA-ergic (right) hippocampal autaptic neuron. 
The identity of the two types of autaptic cells was confirmed by retrospective 
biophysical and pharmacological analysis of evoked currents. Scale bar, 100 μm. 
B. Representative eEPSCs (left) and eIPSCs (right) traces evoked in excitatory 
and inhibitory autaptic cells from WT (black traces) or PRRT2-KO (red/blue traces 
for EPSCs and IPSCs, respectively) mice. Currents were elicited at Vh = -70mV 
and stimulating it with two 0.5 ms steps to 40 mV separated by the indicated ISIs 
and applied at a frequency of 0.1 Hz. C. eEPSC amplitude (left) and PPR as a 
function of ISIs ranging from 20 to 10,000 ms (right) for WT (black bar/symbols) 
and PRRT2-KO (red bar/symbols) neurons. Data were obtained from n=53 WT and 
n=54 PRRT2-KO glutamatergic neurons. D. eIPSC amplitude (left) and PPR as a 
function of ISIs ranging from 20 to 10,000 ms (right) for WT (black bar/symbols) 
and PRRT2-KO (blue bar/symbols) neurons. Data were obtained from n=32 WT 
and n=34 PRRT2-KO GABA-ergic neurons. In all traces, the stimulation artefacts 
were blanked for clarity. Data are shown as means ±sem. *p < 0.05, **p < 0.01 
unpaired Student’s t-test/Mann-Whitney's U-test. 
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 3.2. Excitatory and inhibitory PRRT2-KO neurons respond 
differently to high-frequency stimulation 
 
The effects of PRRT2 deletion on the excitatory and inhibitory synapses 
and by modulation of the PPR led us to study the short-term plasticity (STP) 
properties of these synapses. We have conducted this study using short (2 
s) stimulation trains with increasing frequency (from 5 to 40 Hz). These 
protocols promote Ca2+ rise in the nerve terminal and the progressive 
depletion of the Readily Releasable Pool (RRP) (Fioravante and Regehr, 
2011). The results were similar to those obtained analyzed PPR. Excitatory 
synapses of PRRT2-KO neurons displayed a larger facilitation than WT 
synapses in the high frequency range and a milder depression in the low 
frequency range (Fig. 9 A, B). By contrast, inhibitory PRRT2-KO synapses 
showed a faster depression in response to 20 and 40 Hz trains without 
change in the response to trains of 5 and 10 Hz (Fig. 9 C, D).  
These findings suggest that PRRT2 deletion has a presynaptic effect most 
likely on the Pr. Thus, a protocol of stimulation consisting of a train of 40 
Hz, which is used to promote a full RRP depletion, was used to study the 
quantal parameters of release in both excitatory and inhibitory synapses 
using the cumulative PSC amplitude analysis (Fig. 10 A, D). The same 
changes in the current amplitude of synchronous release observed in 
excitatory and inhibitory PRRT2-KO synapses were attributable to opposite 
changes in the initial Pr, without any detectable effect on the RRPsyn total 
current (Fig. 10 C, F; middle panels).  
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Figure 9. PRRT2 deletion enhances facilitation of glutamatergic synapses 
and produces a more profound synaptic depression compared with GABA-
ergic synapses. A, C. Representative recordings of eEPSCs (A) and eIPSCs (C) 
evoked by 2 s tetanic stimulation at 5 Hz administered to WT (black traces) or 
PRRT2-KO (red/blue traces for EPSCs and IPSCs, respectively) autaptic 
hippocampal cultures. B, D. Mean ±sem of normalized values of eEPSC (B) and 
eIPSC (D) amplitude showing the time course of synaptic facilitation and/or 
depression evoked in WT (black traces) or PRRT2-KO (red and blue traces for 
EPSCs and IPSCs, respectively) autaptic hippocampal neurons in response to 2 s 
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tetanic stimulations at 5, 10, 20 and 40 Hz. The shaded areas in the 5 Hz panels 
refer to the representative traces shown in A and C. The insets in the 20 and 40 Hz 
panels report the mean ±sem of the extent of facilitation (B) or depression (D) 
representing the second stimulus in the train. Data were obtained from: 5 Hz (WT, 
n=16; PRRT2-KO, n=18), 10 Hz (WT, n=21; PRRT2-KO, n=20), 20 Hz (WT, n=21; 
PRRT2-KO, n=20) and 40 Hz (WT, n=22; PRRT2-KO, n=21). *p < 0.05, unpaired 
Student’s t-test/Mann-Whitney’s U-test. 
 
 
 
Figure 10. Constitutive PRRT2 deletion shows opposite effects on release 
probability in excitatory and inhibitory PRRT2-KO neurons. A, D. 
Representative recordings of eEPSCs (A) and eIPSCs (D) evoked by 2 s tetanic 
stimulation at 40 Hz administered to WT (black traces) and PRRT2-KO (red/blue 
traces for EPSCs and IPSCs, respectively) autaptic hippocampal neurons. B, E. 
Cumulative amplitude profiles of eEPSCs for WT (n=22) and PRRT2-KO (n=21) 
neurons subjected to 40 Hz stimulation for 2 s. Data points in the 1- to 2-s range 
were fitted by linear regression and back-extrapolated to time 0 (solid lines) to 
estimate the RRPsyn. C, F. Mean ±sem amplitude of the first eEPSC in the train 
used to perform quantal analysis (left), RRP syn size (middle) and Pr (right) 
estimated in WT and PRRT2-KO autaptic neurons (WT, n=22; PRRT2-KO, n=21). 
*p < 0.05, unpaired Student’s t-test/Mann-Whitney’s U-test. 
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3.3. Primary PRRT2-silenced networks display a state of 
spontaneous hyperactivity and robust synchronization in 
bursting events 
 
Since we observed the alterations in both excitatory and inhibitory synaptic 
transmission at single-cell level, we then investigated the functional 
consequences of these changes at the network level. To address this issue 
we plated the primary hippocampal neurons onto multi-electrode array 
(MEA) chips (Fig. 11 A, left). By this approach, we monitored spontaneous 
activity of PRRT2-KO and WT primary hippocampal neurons at high 
density, in time periods ranging from early synapse formation (14 DIV) to 
that of mature synaptic connections (21 DIV). Fig. 11 A (right) showed 
raster plots of the spiking activity recorded from representative PRRT2-KO 
and WT networks. Basal activity from representative networks of both 
genotypes was characterized by the occurrence of isolated spikes, single-
channel bursts and synchronous array-wide bursts (raster plots and inset, 
Fig. 11 A), lasting from few hundreds ms up to 1 s (Van Pelt et al., 2004, 
Chiappalone et al. 2007; Vajda et al. 2008). Periodic population bursts 
activity in primary neuronal cultures is a sign of global network 
synchronization that closely depends from synaptic connectivity and basal 
intrinsic excitability (Maeda et al. 1995, Penn et al. 2016; Suresh et al. 
2016). Under our experimental conditions, we reported that only 55.1% of 
the WT cultures (29 cultures out of 49) versus 86.9% of the KO (40 out of 
46) generated networks bursts (Fig. 11 A, right panel). The main activity 
parameters, evaluated at a mature stage of in vitro development, showed 
an increased network mean firing rate in the network of PRRT2-KO cultures 
compared to WT cultures (Fig. 11 B). We observed a hyperactivated 
PRRT2-KO, in line with the increased synaptic facilitation of excitatory 
transmission that strongly impairs activity dynamics in reverberant networks 
(Abbott and Regehr, 2004). The average network bursting rate and the 
intraburst firing rate in PRRT2-KO neurons were significanty higher than 
that in WT neurons, with a decrease in the bursts duration (Fig. 11 B). 
Moreover, the value of bursts percentage (the fraction of total spikes within 
bursts) was significantly higher than in WT cultures. The synchrony index, 
representing the degree of synchronization of bursting activity throughout 
each networks (Paiva et al., 2010), was markedly increased in PRRT2-
silenced cultures with respect to WT condition. These data confirm that 
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mature PRRT2-KO networks express a more pronounced synchronization 
in their bursts behaviours (Fig. 11 B). We hypothesized that the shorter 
network bursts observed in silenced cultures could be due to the increased 
inhibitory network activity described in the analysis of synaptic properties, 
or to a faster depletion of synaptic resources during high-frequency 
synchronized activity (Cohen and Segal, 2011).  
Furthermore, to test whether the described changes of inhibitory 
transmission could have an impact on the spontaneous hyperactivity of 
PRRT2-KO networks, the effect of an acute treatment with bicuculline of 
mature cultures (BIC, 30 µm, blocking GABAA receptors) was investigated 
(Chiappalone et al., 2009; Lignani et al., 2013). In both WT and silenced 
neurons, raster plots showed that BIC treatment increased bursting activity, 
while random spiking was completely abolished (Fig. 11 C). Moreover, in 
WT networks, BIC induced an increase in the values of firing rate, bursting 
rate and burst duration, while it decreased the value of intra-burst firing rate 
(Fig. 11 C). The same qualitative changes were observed in PRRT2-KO 
networks, but quantitatively more pronounced (Fig. 11 C). To compare the 
effect of the BIC treatment across genotypes, the values of individual 
network activity parameters were normalized to the corresponding values 
before drug administration (BIC/base ratio; right panels in Fig. 11 C). The 
BIC/base ratios for firing rate, bursting rate, burst percentage were 
significantly higher for PRRT2-KO networks than for WT networks. The 
enhancement of the differences between the two conditions under BIC is in 
line with the strengthened inhibitory tone observed in whole-cell patch-
clamp recordings in silenced neurons. 
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Figure 11. PRRT2-KO hippocampal networks display heightened excitability 
under basal conditions and under blockade of GABAA-mediated inhibitory 
transmission. A. Phase contrast micrograph of WT network over a MEA at 14 DIV 
and spiking activity recorded from four adjacent microelectrodes are showed in the 
top and bottom left panels, respectively.  Electrophysiological spontaneous activity 
from WT or PRRT2-KO primary hippocampal networks was recorded between the 
second and the third week in vitro (14-21 DIV). On the last day of the experiments, 
networks were challenged with bicuculline (BIC, 30 μM), the GABAA receptor 
blocker. In the panels on the right, raster plots of spiking activity recorded over 60 s 
from WT and PRRT2-KO cultures. Each row is an electrode of the array and marks 
represent APs. The magnification shows spontaneous population bursting 
generated by a mature WT culture (inset). Collective bursts lasted few hundreds of 
milliseconds and were separated by longer periods of scarce firing activity as 
highlighted in the panel inset. The bar plot shows the fraction of networks 
generating population bursts, expressed as a percentage of total cultures for each 
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genotype.  B: Main firing and bursting parameters measured for WT (black) and 
PRRT2-KO (red bars) cultures at 14 and 21 DIV. From left to right: firing rate, 
network bursting rate, network burst duration, intra-burst firing rate, burst 
percentage and synchrony index measured for each experimental group during the 
third week in vitro (n=4 independent preparations for each genotype, 49 and 46 
independent experiments for WT and PRRT2-KO, respectively). C. Left: Raster 
plots of the activity recorded from WT and PRRT2-KO cultures in the presence of 
BIC (30 M) over 60 s. Right: Statistical analysis of the effect of BIC treatment on 
firing rate, network bursting rate, network burst duration and intra-burst firing rate 
expressed as ratios between individual values of each network parameter under 
BIC and the corresponding values under basal conditions (BIC/base ratio) (n=3 
independent preparations for each genotype, 32 and 31 independent experiments 
for WT and PRRT2-KO, respectively). Data are plotted as means ±sem for WT 
(black) and PRRT2-KO (red bars) cultures. Unpaired Student’s t-test/Mann-
Whitney's U-test was used to compare the activity parameters (Fig. 11 B) and the 
BIC/Base ratios (Fig. 11 C) across genotype (*p < 0.05; **p < 0.01, ***p < 0.001). 
The effects of BIC within genotype were analyzed by either Wilcoxon or paired 
Student's t-test (°p < 0.05; °°p < 0.01; °°°p < 0.001). 
 
 
3.4. PRRT2 silencing is associated with an increase of intrinsic 
excitability of hippocampal excitatory neurons 
 
MEA analysis showed a general hyperactivity of PRRT2-KO networks 
compared to WT. In order to get insights in the underlying mechanism, we 
performed electrophysiological analysis at single-cell level on excitatory 
pyramidal neurons in low-density hippocampal network. These cells were 
visually inspected and retrospectively determined (Pozzi et al., 2013). The 
macroscopic Na+ and K+ currents were studied by voltage steps of 
increasing amplitude and ramp protocol (Fig. 12 A, protocols are showed 
as inset). Analysis of the density-voltage relationship (JNa+/V) of Na+ 
current showed a significant increment of JNa+ in PRRT2-KO hippocampal 
neurons compared to WT (Fig. 12 B). This effect was not accompanied by 
changes of the K+ current density (JK+) of both phenotypes measured at 
+120 mV (Fig. 12 C).  
We next studied the spontaneous and evoked firing activity under current 
clamp condition. The spontaneous firing of PRRT2-KO neurons clamped 
near the threshold (Vh =-40 mV) by injection of a constant depolarizing 
current was significantly higher than that observed in WT neurons analysed 
under the same conditions (Fig. 12 D, E). Next, we also depolarized the 
neuronal membrane potential with subsequent current steps injection of 5 
pA to evoke the firing activity. Mutant neurons showed a higher evoked 
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firing activity compared to WT neurons, as depicted from the analysis of 
mean firing rate calculated as the ratio of the number of APs evoked by the 
minimal current injected to the time interval in seconds between the first 
and the last evoked AP (Fig. 12 F, G). It is well known that neurons present 
the ability to show adaptation to current steps stimulation, which increases 
their firing frequencies (Awiszus et al., 1988). Thus, we finally evaluated the 
adaptation of excitatory hippocampal neurons injecting 5 ms supra-
threshold current steps, administered at frequencies from 10 to 120 Hz 
(Fig. 12 H). For each stimulation frequency tested, the percentage of 
evoked APs over the total number of stimuli was calculated in both 
phenotypes. The two neuronal populations were able to fire the 100% of 
APs up to 40 Hz. Interestingly, over this frequency, WT neurons displayed a 
progressively increasing amount of failures, while PRRT2-KO neurons were 
able to sustain higher stimulation frequencies (from 80 to 120 Hz) with a 
significantly higher probability of success (Fig. 12 I).  
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Figure 12. PRRT2-KO excitatory neurons show an increased intrinsic 
excitability. A, B. Representative whole-cell macroscopic currents (A) evoked by a 
family of 10 mV depolarizing voltage steps or a ramp protocol (insets) and (B) 
current density vs voltage relationship, calculated using the protocol shown in 
panel A. Excitatory hippocampal WT neurons (n=58) are showed with black 
symbols/traces; PRRT2-KO neurons (n=54) with red symbols/traces. C. J at +120 
mV for WT/PRRT2-KO genotypes calculated using the ramp protocol (lower part of 
panel A) (WT, n=58; PRRT2-KO, n=54). D, E. Representative voltage trace 
recordings (D) of spontaneous APs generated by WT and PRRT2-KO neurons 
during the injection of a constant depolarizing current to maintain the membrane 
potential at the threshold (Vh ≅−40 mV) and mean ±sem of spontaneous firing 
frequency (E)  recorded using the protocol shown in D (WT, n=21; PRRT2-KO, 
n=22). F, G. (F) Representative current-clamp recordings of action potentials 
evoked by the injection of -50, 0 and +200 pA steps of 1 s duration (inset) and 
statistical analysis of mean ±sem firing frequency (G) observed in WT (n=56) and 
PRRT2-KO (n=60) neurons. H, I. Representative current-clamp traces of action 
potentials activated by 20 current steps (5 ms) at 80 Hz (H) and mean ±sem of the 
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probability to evoke action potentials in WT (n=59) and PRRT2-KO (n=63) neurons 
(I) at increasing frequencies of current injection. The percentage of the amount of 
injected current was reported as the minimal current able to evoke 100% of APs at 
10 Hz.  *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t-test/Mann-
Whitney's U-test. 
 
 
3.5. IPSCs are generated and characterized from fibroblasts of 
patients carrying the PRRT2 c.649dupC mutation 
 
The results of the electrophysiological characterization showed that 
PRRT2-KO neurons have a sustained increase of single-cell and network 
excitability compared to WT cells. In an attempt to understand the 
molecular basis of the PRRT2-associated dysfunctions, we generated and 
characterized iPSCs from fibroblasts of patients from a consanguineous 
Italian family (Labate et al., 2012), carrying the c.649dupC common loss-of-
function mutations in heterozygosity (Patient P1) or homozygosity (Patients 
P2 and P3, siblings of P1). As control we have used iPSCs generated from 
sex- and age-matched normal donors (C1 and C2). P1 generally presented 
a self-limiting seizure of childhood, whereas P2 and P3 showed a more 
severe phenotype with co-occurrence of other forms of PDs (see Table 4). 
To generate iPSCs, fibroblast cells were transfected with retroviral 
reprogramming factors (OCT3/4, SOX2, KLF4 and C-MYC, see Introduction 
and Materials and Methods).  
In order to assure high quality of iPSC clones, expression analyses for 
known pluripotency marker expression by qRT-PCR and 
immunofluorescence were performed. By analysis of qRT-PCR 
experiments, we confirmed that iPSCs expressed pluripotent stem cells 
markers. As a negative control, fibroblast culture that showed any 
expression of these pluripotency markers was used (Fig. 13 A, opens bars 
in the graphs). A second step in the cell characterization includes the 
determination of iPSC clone’s ability to differentiate into cells of the three 
germ layers: endoderm, mesoderm and ectoderm (Fig. 13 E-G). To 
perform this test, cells were differentiated into the type of germ layers using 
defined medium containing the necessary differentiating factors and then 
we evaluated the expression of germ layer markers. This assay confirmed 
the pluripotency of the generated iPSCs. Only the iPSC clones that passed 
this test of staminality were used subsequently for differentiation into 
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neurons. The neuronal differentiation in vitro goes through to different steps 
(Fig. 14 A). In the first phase, iPSC clones produce EBs that consist of 
three-dimensional aggregates formed in suspension like “neurosphere”. 
Then, upon dissociation and plating onto substrate, these cells generate 
adherent neural rosette upon exposure to small-molecules that inhibit the 
Bone Morphogenetic Protein and the Transforming Growth Factor-β 
signaling. By the inhibition of these two antineurogenic factors, the 
production of proteins that interfere with the transcriptional activities of 
proneural proteins in neural progenitor cells is blocked, inducing the 
generation of neuronal rosette. 
In this study, rosettes were co-cultured with embryonic rat cortical neurons 
(see Materials and Methods) used as feeder layer. This feeder layer were 
important to induce normal neuronal differentiation of our cells. It was also 
found that adding common neural modulating molecules, such as retinoic 
acid, BDNF and GDNF to the neuronal differentiation medium in the last 
phase of the treatment, greatly enhanced neuronal differentiation and 
maturation, which resulted in the generation of a stable population of self-
renewal NPCs. After 25-30 days of co-culture, neurons derived from iPSCs 
cells reached a mature state with neuronal-like morphology.  
Gene expression profiling showed that NPC-differentiation markers were 
upregulated in all NPC populations compared to the parental iPSCs, 
whereas specific pluripotency genes where downregulated (Fig. 14 B). 
Moreover, immunofluorescence analysis indicated that NPCs were positive 
for the neural cell markers SOX1, SOX2, NESTIN and the dorsal 
telencephalic marker PAX6. These data clearly indicate that our cells have 
a clear cortical progenitor fate (Fig. 14 C, D).  
IPSCs-derived neurons were positive for typical markers of neuronal 
differentiation: Neuronal Nuclei (NeuN) and Microtubule-Associated Protein 
2 (MAP2). NeuN is a neuron-specific protein that has a role in regulating 
neural cell differentiation and nervous system development (Kim et al., 
2009) and MAP2 is a neuron-specific cytoskeletal protein involved in 
determining and stabilizing dendritic shape during neuronal development 
(Geisert et al., 1990) (Fig. 14 E, G). The percentage of NeuN+ cells was 
very similar across all the clones tested (Fig. 14 F). IPSC-derived neurons 
expressed also VGLUT1 and GABA, two markers of excitatory and 
inhibitory cells, respectively (Fig. 14 H, I). This evidence supports the 
notion that under our conditions both type of neurons are present, forming a 
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mixed network. Furthermore, we studied the iPSC-derived neurons 
concerning the expression of NaV channels, which are essential to shape 
the excitability of mature neurons. To this end, we used a specific antibody 
against α-subunits of NaV channels. We observed that all genotypes of 
human neurons expressed this subunit at the AIS (Fig. 14 J). At a 
functional level, whole-cell voltage-clamp recordings showed the presence 
of inward currents with fast activation and inactivation kinetics fully 
blocked by TTX in all genotypes (Fig. 14 K, left). The TTX blockade was 
evident at every potential tested (Fig. 14 K, right).  
Taken together, these data suggest that mature functional neurons were 
obtained under our conditions in vitro. 
 
 
 
Figure 13. Validation of iPSC lines generated from fibroblasts of patients 
carrying c.649dupC mutation in PRRT2 gene A. Quantification by RT-qPCR 
analysis of the expression levels of different pluripotency markers in the different 
clones obtained from heterozygous Patient 1 (P1.30, P1.35 and P1.45, green 
bars), from homozygous Patient 2 (P2.5, P2.18, red bars) and Patient 3 (P3.30, 
orange bar) and from two unrelated non-carrier individuals (C1.25, C1.28, C1.32, 
black bars; C2.6, grey bar). Data are means ±sem (n=3) of relative expression 
using non-infected fibroblasts from a control (Ctr) as reference (open bars). B. 
54 
 
Morphology of an iPSC clone at the undifferentiated state. Scale bar, 50 µm. C-D. 
Representative immunofluorescence images showing the expression of 
pluripotency markers (OCT4, SSEA4, TRA1-60 and SOX2) in iPSC lines (nuclei 
were stained with DAPI; Scale bar, 100 μm). E-G. IPSC clones generate cells of 
the three germ layers: ectodermal (TUJ1), mesodermal (α-SMA) and endodermal 
(AFP) markers (nuclei were stained with DAPI; scale bar, 50 μm). 
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Figure 14. Neuronal differentiation and characterization of iPSC-derived 
neurons. A. Scheme for the generation of iPSCs and representative images at 
different steps of the neuronal differentiation. From the left: representative iPSC 
colony, embryoid bodies (EBs), neural rosettes, NPCs and representative live 
image of iPSCs-derived neurons (GFP+, green), co-cultured with cortical rat 
neurons (TdTomato+). Scale bar, 50 µm. B. Quantification by RT-Q PCR analysis 
of the NPC gene expression profile. NPC-specific markers SOX1 and PAX6 are 
upregulated in NPCs, as compared to iPSCs. NESTIN and SOX2, participating in 
self renewal and neural differentiation, are expressed by both cell types. The 
pluripotency specific gene NANOG is strongly downregulated in NPCs. Data are 
means ±sem of relative expression using iPSCs as reference. C, D. Representative 
immunofluorescence images of neuronal rosettes showing expression of NPC 
markers (C: SOX2, red; NESTIN, green; D: PAX6, red; SOX1, green). E, G. 
Representative immunofluorescence images of the immunoreactivity of iPSC-
derived neurons for mature neuronal markers NeuN (quantified in F) and MAP2 (G) 
after four weeks of differentiation. Scale bar, 10 µm. F. Data are expressed as 
means ± SD of n=3 independent experiments (at least 50 cells each experiment). 
One clone for each genotype is shown. Not significant, Kruskal-Wallis/Dunn’s test. 
H, I. Representative immunofluorescence images of VGLUT1- and GABA-positive 
cells. Scale bar, 10 µm. J. Representative immunofluorescence of iPSC-derived 
neurons expressing voltage-gated Na+ channels. The inset shows colocalization of 
GFP and PanNaV at the AIS. Nuclei were stained with DAPI. Scale bar, 5 μm. K. 
Left: Representative whole-cells currents elicited by depolarizing C1.28 neurons 
with a family of 10-ms depolarizing voltage steps (inset) in the absence (black) or 
presence of TTX (1 µm, blue). Right: Current density vs voltage relationship for 
C1.28 neurons exposed to either vehicle or TTX (1 μm; n=9).  
 
 
3.6. Homozygous iPSC-derived neurons display increased Na+ 
current densities 
 
In the next set of experiments we have studied in detail the functional 
properties of the generated neurons. To this end we characterized the 
electrophysiological properties of all the produced clones of human neurons 
obtained from the heterozygous patient P1 (P1.30), the two homozygous 
patients P2 and P3 (P2.5 and P3.30) and the two healthy controls C1 and 
C2 (C1.28 and C2.6). Single-cell neuronal excitability was studied by 
measuring the macroscopic Na+ and K+ conductance evoked by a family of 
voltage-steps and by ramp protocol (Fig. 15 A). Before functional 
characterization, the level of PRRT2 mRNA in these clones has been 
quantified. The analysis of PRRT2 mRNA expression by qRT-PCR in the 
various neuronal preparations showed that the homozygous clones had 
very low levels of PRRT2 mRNA with respect to the healthy controls, while 
the heterozygous clone expressed intermediate levels (Fig. 15 B). 
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Functional analysis indicated that both homozygous clones displayed 
greatly increased fast-inactivating inward currents in response to voltage-
steps and ramp stimulations, while the peak outward currents recorded at 
+120 mV, were comparable in all genotypes tested. These results were 
evident also from the inspection of the Na+ current density (JNa+)-voltage 
relationship and of the bar-graph of maximal JNa+ (Fig. 15 C, D; left). The 
increase in JNa+ at -5 mV in either homozygous clone (P2.5 and P3.30) 
was significantly higher than that recorded in either control clone, as well as 
in the heterozygous clone, which was not significantly different from 
controls (Fig. 15 E, left). At variance, no significant differences were 
observed in the JK+ measured at +120 mV across all genotypes (Fig. 15 D, 
E; right). 
We also tested supplementary iPSC clones, derived from the same healthy 
individual C1 (C1.25, C1.32) and patients P1 and P2 (P1.35, P2.18) that, 
compared to control neurons, displayed significant increase in JNa+ in 
homozygous neurons, but not in heterozygous (Fig. 16 A, B). The 
statistical analysis of JK+ at +120 mV showed no differences between each 
genotypes (Fig. 16 C). 
Taken together, these data show that iPSC-derived neurons obtained from 
fibroblasts of two homozygous PRRT2 patients display an increase in 
voltage-gated Na+ current compared to control and heterozygous neurons. 
These results are very interesting because, whereas the common 
heterozygous PRRT2 mutations are associated with relatively mild and 
pleiotropic phenotypes, the very rare homozygous mutations hitting both 
alleles cause severe syndromic forms, cause all the isolated paroxysmal 
phenotypes with ataxia, PKD, severe epilepsy and are often associated 
with intellectual disability (Labate et al., 2012; Liu et al, 2016). 
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Figure 15. Patient iPSC-derived neurons show an increase of Na+ channels 
current. A. Representative whole-cell families currents recorded in C1.28, C2.6 
(from controls), P1.30 (from heterozygous Patient 1) and in P2.5 and P3.30 clones 
(from homozygous Patient 2 and 3). Currents were elicited using a family of 
depolarizing 10 ms voltage steps or a ramp protocol (inset). Cells were clamped at 
-70 mV before stimulation. B. Amount of PRRT2 mRNA expression tested by qRT-
PCR in iPSC-derived neurons (25 days of differentiation). Results are expressed 
as means ±sem of n=3 independent experiments. *p< 0.05; Kruskal-Wallis/Dunn’s 
tests. C. Current density vs voltage relationship for C2.6, P2.5 and P3.30 (left) and 
C1.28, P1.30 (right) iPSC-derived neurons, calculated using the protocol shown in 
panel A. Neurons were grouped in two distinct panels for clarity. D, E. Statistical 
analysis of the current density (as shown in panel C) at -5 mV (left) and at +120 mV 
(right) for clones C2.6, P2.5, P3.30 (D), C1.28 and P1.30 (E). The current density 
at +120 mV was calculated by the ramp protocol represented in panel A (as inset). 
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Data are shown as means ±sem (n=20 for C1.28, n=34 for C2.6, n=29 for P1.30, 
n=32 for P2.5 and n=19 for P3.30). ***p<0.001 Kruskal-Wallis/Dunn’s tests. 
 
 
 
Figure 16. Homozygous neurons derived from different iPSC clones show the 
same increase in Na+ current. A. Current density vs voltage relationship for 
C1.25 and P2.18 (left panel) and C1.32 and P1.35 (right panel) iPSC-derived 
neurons, analysed using the protocol shown in Fig. 15 A (inset). B. Statistical 
analysis of the current density at -5 mV (left) and at +120 mV (right) for clones 
reported in panels A-B. The current density calculated at +120 mV was analysed 
by the ramp protocol reported in Fig. 15 A (inset). Data are shown as mean ±sem. 
*p<0.05 vs C1.28, ##p<0.01, ###p<0.001 vs C2.6; Kruskal-Wallis/ Dunn’s tests. 
 
 
3.7. Homozygous iPSC-derived neurons have an altered intrinsic 
excitability rescued by the reintroduction of human wild-type 
form of PRRT2 
 
Since the homozygous reprogrammed neurons showed an increase of 
voltage-gated Na+ conductance, and because this conductance plays a 
central role in the control of cellular excitability, we next investigated further 
this genotype in order to study the intrinsic excitability properties. 
To verify whether the observed phenotypic changes were due to the lack of 
PRRT2 protein, its expression was rescued in the homozygous neurons by 
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infection with lentivirus encoding Cherry-tagged WT human PRRT2. The 
P2.5-derived neurons were alternatively transduced with the PRRT2-Cherry 
or with the Cherry-alone virus as a control (MOCK), while control C1.28-
derived neurons were only infected with Cherry-alone virus. Exogenous 
PRRT2 was correctly expressed in P2.5-derived neurons and the mRNA 
levels of PRRT2, determined by qRT-PCR, were greatly increased (Fig. 17 
A, B). 
Electrophysiological analysis confirmed the sustained increase of the JNa+ 
in the MOCK-transduced P2.5 neurons observed before, whereas the re-
expression of PRRT2-WT decreased it compared to the MOCK-transduced 
control (C1.28), suggesting a dose-dependent modulation of NaV channels 
activity operated by PRRT2 (Fig. 17 C, D).  
Because NaV channels play a critical role in the initiation and propagation of 
APs in neurons, we next analysed the firing properties of both types of 
human-derived neurons. These properties were studied by delivering 
constant current pulses (1 s of duration) of increasing amplitude (5 pA 
steps) and then studying the resulting APs activated (Fig. 17 E). We 
observed that homozygous iPSC-derived neurons responded to the 
injection of a depolarizing current with APs firing whose frequency did not 
differ from control neurons. In contrast, re-expression of PRRT2 WT in 
homozygous neurons significantly decreased the evoked firing activity (Fig. 
17 E, F). Homozygous iPSC-neurons exhibited a decreased input 
resistance and threshold for AP generation, and an increase of AP peak, 
amplitude and maximal slope of the rising phase of AP (Fig. 17 G). Of note, 
all these changes observed in homozygous neurons were fully normalized 
when WT form of human PRRT2 was reintroduced (Fig. 17 G). In 
summary, these experiments demonstrate, for the first time, that iPSC-
derived neurons obtained from fibroblasts of two homozygous PRRT2 
patients display increased excitability and increased voltage-gated Na+ 
current. They also show that iPSC-derived neurons from the heterozygous 
sibling exhibited electrical features that parallels the mild and age-
dependent clinical manifestations. Finally, we show that the phenotype of 
homozygous iPSC-derived neurons is totally rescued by re-expression of 
WT human PRRT2. 
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Figure 17. Homozygous iPSC-derived neurons have an altered excitability 
that is rescued by the reintroduction of human WT form of PRRT2. A. 
Representative image of fluorescence of homozygous P2.5 neurons infected with a 
Cherry lentivirus (red) used as reporter of PRRT2 expression. Scale bar, 20 µm. B. 
Expression of PRRT2 mRNA in MOCK-transduced C1.28 (black), MOCK-
transduced P2.5 (red) and PRRT2-rescued P2.5 (blue) iPSC-derived neurons (25 
days of differentiation). Results are expressed as means ±sem of n=3 independent 
experiments. C. Current density vs voltage relationship for the MOCK-transduced 
C1.28 and P2.5 iPSC-derived neurons and P2.5 cells in which PRRT2 expression 
was rescued (P2.5+ PRRT2). D. Statistical analysis of the J at -5 mV (left, for all 
conditions plotted in C) and at +120 mV. Data are expressed as means ±sem 
(n=35 for C1.28, n=31 for P2.5, n=26 for P2.5+PRRT2). E. Representative current-
clamp recordings of APs evoked by the injections of 5 pA step current (1-s 
duration; protocol shown in the inset) for C1.28, P2.5 and P2.5+PRRT2 iPSC 
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neurons F. Mean and Instantaneous firing frequency of analysed conditions 
expressed as means ±sem. G. Input Resistance, Voltage Threshold of action 
potentials activation, Maximal voltage (Vmax), Amplitude and Maximal slope (slope 
max) of action potentials calculated for the first action potential evoked by minimal 
injection of current from all studied conditions. Data are shown as means ±sem 
(n=28 for C1.28, n=33 for P2.5, n=19 for P2.5+ PRRT2). In panels B, D, F, G: 
*p<0.05, **p<0.01, ***p<0.001 vs MOCK-transfected C1.28; #p<0.05, ##p<0.01, 
###p<0.001 vs MOCK-transfected P2.5; Kruskal-Wallis/Dunn’stests. 
 
 
3.8. PRRT2 modulates NaV1.2 and NaV1.6 channel conductance 
when expressed in HEK-293 cells 
 
Excitability properties of neurons derive from the integration of excitatory 
and inhibitory synaptic inputs at the AIS of the neuronal cells. At this level, 
clusters of distinct NaV channel subtypes generate APs (Kole et al., 2008). 
It has been reported that glutamatergic neurons display an abundant 
expression of subtypes NaV1.2 and NaV1.6 at the proximal and distal part of 
AIS respectively, while NaV1.1 is particularly abundant in the AIS of GABA-
ergic neurons (Mantegazza and Catterall, 2012). With the aim to unveil the 
mechanistic insights that underlie the increase of JNa+ and the rise of 
intrinsic cellular excitability observed in iPSC-derived neurons, we 
performed whole-cell patch-clamp experiments on HEK-293 stably 
expressing the different subtypes of human NaV channels 1.1, 1.2 and 1.6. 
HEK-293 cells stably expressing NaV1.1, NaV1.2 or NaV1.6 channels were 
transfected with the human form of full-length protein PRRT2 and with 
empty vector (MOCK), used as control. Strikingly, in the absence of 
channel inactivation (Vh= -120 mV), PRRT2 expression significantly 
reduced the Na+ current amplitude (Fig. 18 A) and density (Fig. 18 B) in 
NaV1.2 and NaV1.6 but not in NaV1.1 expressing cells. The fast inactivating 
voltage-gated Na+ currents were studied by delivering 100 ms steps from -
80 to +65 mV (Vh = -120 mV) with 5 mV increments (Fig. 18 A, inset), and 
were used to obtain the JNa+/V relationship under all conditions tested. 
The decrease of Na+ current recorded mediated by NaV1.2 and NaV1.6 
channels, when PRRT2 was expressed, was not accompanied by any 
significant variation of the normalized conductance-voltage (G/Gmax-V) 
curves, suggesting that PRRT2 does not affect the voltage-dependent 
activation of these channels (Fig. 18 C). In contrast, the voltage-
dependence of fast inactivation was shifted to more negative potentials in 
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the presence of PRRT2 in both NaV1.2 and NaV1.6, but was unaffected in 
NaV1.1-expressing cell lines (Fig. 18 D). The inactivation was more 
negative in HEK-293 NaV1.2 and NaV1.6 in the presence of PRRT2 of 
about 10 mV and 6 mV, respectively (Fig. 18 D, right panels).  
These results indicate that a sustained negative modulation of the current 
density occurs when PRRT2 is co-expressed with NaV1.2 or NaV1.6 but not 
when PRRT2 is co-expressed with NaV1.1. This negative modulation by 
PRRT2 is accompanied by changes in the voltage-dependence of 
inactivation which render these channels less excitable under resting 
conditions.  
 
 
Figure 18. PRRT2 expression decreases the Na+ current density of NaV1.2 
and NaV1.6, but not of NaV1.1, stably expressed in HEK-293 cells. A. 
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Representative traces of whole-cell recordings on HEK-293 clones stably 
expressing NaV1.1 (left), 1.2 (middle) and 1.6 (right) and transiently transfected 
with empty vector (MOCK, black) or PRRT2 (blue). Currents were activated by 5 
mV steps depolarization from -80 to 65 mV (Vh= -120 mV, inset). B. Current density 
vs voltage relationship for all conditions described in panel A. C. Voltage-
dependence of activation for the three subtypes of NaV channels co-expressed with 
MOCK or PRRT2. The lines are the best-fitted Boltzmann curves with the following 
mean values of half maximal voltage activation (V0.5) and slope (k): NaV1.2, MOCK, 
V0.5: -23.89±0.19 mV, k: 4.39±0.16 (n=22), PRRT2 V0.5: -24.16±0.21; k: 4.37±0.19 
(n=20); NaV1.6, MOCK, V0.5: -19.81±0.14 mV, k: 6.99±0.12 (n=27), PRRT2 V0.5: -
20.46±0.17, k: 6.83±0.15 (n=29). D. Steady-state inactivation curves for all 
conditions tested. The lines are the best-fitted Boltzmann curves and the half-
maximal voltages for inactivation (V0.5 inact.) was graphed on the right. Data are 
means ±sem (NaV1.2: MOCK, n=22 and PRRT2, n=18; NaV1.6: MOCK, n=24 and 
PRRT2, n=21). ***p<0.001; unpaired Student's t-test or Mann-Whitney U-test. 
 
 
3.9. PRRT2 specifically interacts with NaV1.2 and 1.6 α-subunits 
and regulates their surface expression 
 
The electrophysiological results obtained in PRRT2-KO neurons, in iPSC-
derived neurons from homozygous patients and in HEK-293 cells 
heterogously expressing NaV channels, suggest a possible interaction 
between PRRT2 and NaV1.2/NaV1.6 α-subunits. To address this 
hypothesis, a possible interaction between the human form of full-length 
PRRT2 protein and the NaV1.2/NaV1.6 α-subunits was tested.  
To test this possibility, PRRT2 was fused with the HA-tag and the 
interactions with the NaV channel subtypes expressed in HEK-293 were 
evaluated by pull-down assays. The unrelated bacterial alkaline 
phosphatase (BAP) protein was used as control (Fig. 19 A). Co-
immunoprecipitation assays showed that PRRT2 pulled down the 
NaV1.2/NaV1.6 α-subunit, with any precipitation of NaV1.1 (Fig. 19 A). 
These data were in agreement with the patch-clamp experiments in HEK-
293 cell lines expressing different subtypes of NaV. These results combined 
with the effect on the PRRT2-KO neurons and on the iPSC-derived 
neurons, suggest that PRRT2 could be also a modulator of other properties 
of NaV channels, such as channel trafficking, membrane exposure and/or 
stability. 
In order to discriminate between these possibilities, we performed surface 
biotinylation assays in HEK-293 cell lines expressing the various NaV 
subtypes transfected with either PRRT2-HA or an empty vector as control 
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(Fig. 19 B, left panel). We observed that whereas the total levels of each 
NaV α-subunit were unmodified between MOCK- and PRRT2-transfected 
cells, the cell surface abundance of NaV1.2/NaV1.6 was significantly 
decreased in the presence of PRRT2 with respect to control, a result that 
was paralleled by a quantitative similar increase in the intracellular fraction 
(Fig. 19 B, right panel). By contrast, no effect on surface was detected 
about the surface expression of NaV1.1. 
Altogether, these results show that PRRT2 interacts with NaV1.2 and 1.6 
channels exerting a negative modulation on the expression increase of both 
subtypes of NaV. At this point, data also indicate that the JNa+ and the 
hyperexcitability observed in mouse neurons and in PRRT2-KO human 
neurons were correlated to the modulation of functional NaV1.2 and NaV1.6 
channels. These results strongly suggest that PRRT2 could regulate 
neuronal excitability also through the control of the expression at the 
plasma membrane of relevant voltage-gated Na+ channels.  
 
 
 
Figure 19. PRRT2 interacts specifically with NaV1.2 and 1.6 and modulates 
their surface expression. A. Left: Representative immunoblots of NaV1.1, NaV1.2 
and NaV1.6 co-immunoprecipitated by PRRT2. Either HA-tagged PRRT2 (PRRT2) 
or bacterial alkaline phosphatase (BAP) was expressed in HEK-293 cells that 
express human NaV1.1, NaV1.2 or NaV1.6. Cells lysates (INPUT, 10 µg) and 
samples immunoprecipitated by anti-HA beads (IP) were analyzed by Western 
blotting with anti-PanNaV and anti-HA antibodies. Right: Quantification of the 
PanNaV signal in PRRT2 immunoprecipitates normalized to the BAP values. 
Means ±sem of n=3 independent experiments. **p<0.01; ***p<0.001 vs NaV1.1; 
ANOVA/Dunnett’s tests vs NaV1.1. B. Left: Representative immunoblots of cell 
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surface biotinylation performed in HEK-293 cells expressing NaV1.1, NaV1.2 and 
NaV1.6 and transfected with PRRT2-HA or empty vector (MOCK). Total lysates 
(TOTAL), biotinylated (cell surface, EXTRA) and non-biotinylated (intracellular, 
INTRA) fractions were analyzed by Western blotting. Membranes were probed with 
antibodies to PanNaV, PRRT2, Na+/K+-ATPase (Na+/K+) and actin, the latters used 
as markers of cell surface fraction and intracellular fraction, respectively. Right: Cell 
surface and intracellular PanNaV immunoreactivities are expressed in percent of 
the respective MOCK value after normalization to Na+/K+-ATPase (for EXTRA 
fraction) and actin (for INTRA fraction). Means ±sem of n=3 independent 
experiments. *p<0.05; paired Student’s t-test. 
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4. DISCUSSION 
 
Previous studies demonstrated that PRRT2 has a potential role in 
maintaining the pre-synaptic structure and function (Valente et al., 2016a). 
Furthermore, it was suggested that PRRT2 is likely involved in regulating 
synaptic vesicle fusion and the ensuing release of neurotransmitters (Lee 
et al., 2012, Stelzl et al., 2005, Tan et al., 2017, Valente et al., 2016). 
Even though it is well known that the expression of PRRT2 is neuron-
specific although its functions in the regulations of neuronal networks it is 
still largely unknown.  Recent studies have indicated that PRRT2 is the 
major gene at the basis of a broad spectrum of rare infantile neurological 
disorders (Gardiner et al., 2012). It has been shown that heterozygous and 
homozygous mutations of PRRT2 cause impaired or loss-of-function 
expressions of the protein and recapitulate the all paroxysmal phenotypes 
(Labate et al., 2012; Delcourt et al., 2015). 
Several studies have investigated the role of PRRT2 in synaptic 
transmission, both in vitro and in vivo (Liu et al., 2016; Valente et al., 
2016a; Michetti et al., 2017; Tan et al., 2017). PRRT2 is expressed at both 
glutamatergic and GABA-ergic neurons, although it appears more reliably 
targeted at excitatory synapses. A recent work from our laboratory has 
found that an acute downregulation of the PRRT2 gene led to synaptic 
alterations, such as the decrease of synaptic glutamatergic density, but 
without altering its ultrastructure (Valente et al., 2016a). This effect was 
accompanied by an increase in the number of docked SVs, as a result of a 
decreased probability of SVs release in excitatory synapses. In addition, a 
decrease of glutamatergic synchronous release was observed during 
synaptic transmission after acute deletion of PRRT2 by RNA interference 
(Valente et al., 2016a). These data were explained by the tenet that PRRT2 
was functionally linked to the Ca2+-sensitive machinery involved in the 
neurotransmitter release.  
A similar study demonstrated that knocking-down PRRT2 expression in 
vivo by using in utero electroporation of shRNA into cortical neurons 
resulted in a delay in neuronal migration during embryonic development 
and a marked decrease in synaptic density after birth (Liu et al., 2016). 
A recent behavioral study reported that PRRT2-KO mice exhibit the same 
symptoms as patients with PRRT2 diseases (Michetti et al., 2017). Those 
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mice were characterized by wild running and jumping in response to 
intense sensory stimuli and increased sensitivity to the epileptogenic action 
of convulsants. 
All of these data suggest that the alteration of PRRT2 functionality leads to 
an imbalance between inhibitory and excitatory transmission. Therefore, the 
main objective of this doctoral work was to analyze the modulatory role of 
PRRT2 on the electrical properties of neurons by using different 
complementary approaches. So, we generated a human model of PRRT2-
linked diseases based on the generation of iPSC-derived neurons obtained 
from fibroblasts of a consanguineous patients, carrying the c.649dupC 
common loss-of-function mutations in heterozygosity or homozygosity 
(Labate et al., 2012). The latter approach has allowed to compare the 
human KO phenotype with the cellular and network features of mouse 
PRRT2-KO neurons. 
 
 
4.1. Constitutive deletion of PRRT2 alters synaptic connectivity 
 
In this work we have analyzed the electrical properties of primary 
hippocampal neurons in which we constitutively deleted PRRT2 in order to 
create a model for the study of the paroxysmal phenotype in vitro. Data 
from previous works highlighted a possible role of PRRT2 in synaptic 
formation and rearrangement of synaptic connections (Liu et al., 2016; 
Valente et al., 2016a). We evaluated the effect of PRRT2 silencing on the 
spontaneous neurotransmitter release at both excitatory and inhibitory 
synapses. We observed that the phenotype of spontaneous release was 
similar to that observed upon acute silencing of PRRT2 in neurons (Valente 
et al., 2016a). In hippocampal neurons without PRRT2 we observed a 
decreased spontaneous frequency of mEPSCs while other parameters of 
spontaneous release such as amplitude, rise, decay and area were fully 
preserved. This suggests an impairment of spontaneous release at single 
synaptic sites. Since this effect was associated with decreased synaptic 
density in excitatory neurons, these results indicate that the absence of 
PRRT2 causes structural alterations of the synapses (Valente et al., 
2016a). 
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Of note, the lack of PRRT2 in excitatory synapses induced a decrease in 
the probability of release and a slowdown of the release kinetics. Although 
this effect caused a decreased amplitude of evoked excitatory post-synaptic 
current and charge of synchronous glutamate release in response to single 
stimuli, it also led to a markedly strengthening of the facilitation and 
decreased depression during high frequency activity (see, e.g., Millar et al., 
2002). A possible explanation of the decreased Pr of RRP may be that 
residual Ca2+ and the local Ca2+ influx decreases the probability of release 
by altering the binding to different Ca2+ sensors in PRRT2-KO neurons, and 
hence impairing the SVs fusion process. The result of a reduced Ca2+-
sensitivity of release in the absence of PRRT2 suggests that defects 
caused by PRRT2 silencing reside in the dysregulation of the  Ca2+-sensing 
apparatus, as previously reported for the interaction of PRRT2 with SNAP-
25 and Syt1/Syt2 (Valente et al., 2016a). 
Interestingly, a completely different effect was found in GABA-ergic 
neurons. While spontaneous release was not significantly different between 
PRRT2-KO and WT conditions in GABA-ergic neurons stimulated with a 
paired-pulse stimulus, we have observed that the inhibitory strength 
increase due to a parallel increase in Pr. This alteration may reflect an 
adaptive mechanism of plasticity in GABA-ergic transmission in response to 
chronic PRRT2 deletion (see, e.g., Scharfman and Brooks-Kayal, 2014). 
Moreover, this effect was associated with a more profound depression of 
inhibitory transmission in response to both paired stimuli and high 
frequency trains.  
These results demonstrate that STP studied at excitatory and inhibitory 
synapses is affected in opposite way upon PRRT2 deletion. These opposite 
effects support the concept that an alteration of excitation/inhibition 
imbalance in the STP frequency domain might cause a state of 
hyperexcitability/instability in neuronal KO networks. This tenet is supported 
by the view that in general the network dynamics are highly dependent on 
the STP of excitatory and inhibitory synapses, rather than on their basal 
transmission properties (Abbott and Regehr, 2004; Fioravante and Regehr, 
2011). 
From these results, we can conclude that PRRT2 seems to participate in 
the changes of the synaptic homeostasis, affecting glutamatergic synapses 
whereas GABA-ergic synapses are subjected to adaptive changes in the 
absence of this protein. 
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4.2. PRRT2 deletion induces network instability and 
hyperactivity 
 
PRRT2-linked disorders are associated to different symptoms that can be 
due to network instability as result of an alteration of neuronal basal 
electrical and synaptic activities in specific cortical/subcortical areas that 
are normal at rest, but can be imbalanced after external stimulations. In this 
study, we have observed that PRRT2-KO hippocampal networks display 
clear signs of hyperexcitability, resulting in enhanced network 
synchronization and short-term responsiveness to external stimuli.  
The displacement of information in the brain relies on a functional balance 
between excitatory and inhibitory networks. Moreover, in response to 
perturbing conditions that alter network activity, compensatory mechanisms 
are recruited to restore the initial circuit set point (Gao and Wehr, 2015). 
These responses include modulation of excitatory and inhibitory 
postsynaptic strength, alterations in presynaptic neurotransmitter release 
probability, and adjustment of intrinsic membrane excitability (Turrigiano et 
al., 2011). Under these conditions, the extent of network firing activity 
depends from the excitatory/inhibitory balance properties, and hence from 
the STP properties of glutamatergic and GABA-ergic synapses. As STP of 
excitatory synapses acts as a high band-pass filter that propagates high 
frequency activities and prevents the transmission of random low frequency 
(Abbott and Regehr, 2004), the enhanced facilitation of excitatory 
transmission of PRRT2-KO networks during collective high-frequency 
events may be responsible for network hyperactivity and hyper-
synchronization. 
In this study we also report that PRRT2-KO hippocampal neurons have an 
increase of evoked firing properties, a result that was accompanied by an 
increase of Na+ current density in KO cells. This finding could be relevant to 
explain the enhancement of network bursting behavior observed in KO 
network analysed by MEA technology because slow intrinsic neuronal 
properties drive single neurons oscillations and determine their entrainment 
in synchronized collective discharge (Suresh et al., 2016).  
The increase of single cell firing properties together with the enhanced 
bursting activities in the network evoked from spontaneous foci more 
evident in response to localized electrical stimulation that, in PRRT2-KO 
networks, induced a short-lived status of high probability in the discharge of 
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APs. The increase of STP recorded in PRRT2-KO networks also indicates 
a possible role of this protein in the homeostatic control of neuronal 
network. Interestingly, the larger evoked response of PRRT2 networks is 
temporally localized in a brief post-stimulus window followed by a 
subsequent wave of strong synaptic inhibition. This increase of inhibitory 
strength after constitutive inactivation of PRRT2 may suggest the presence 
of a compensatory mechanism that controls and reduces the effect on 
network hyperexcitability. It is well known that PRRT2 is highly expressed in 
different brain areas, including the cerebellum, which is involved in 
processing sensory information of motor skills (Michetti et al., 2017). The 
data indicate a network instability when PRRT2 is chronically inactivated, 
which could explain the motor impairment of patients with PRRT2-related 
disorders associated to aberrant and paroxystic movements. 
 
 
4.3. From PRRT2-KO to iPSC-derived human neurons 
 
While PRRT2-KO model reproduced the phenotype of human PRRT2 
mutations, patient iPSC-derived neurons  provides an applicable platform to 
mimic the human pathogenic process (Takahashi and Yamanaka, 2006) 
and recapitulates the disease in a petri dish, therefore facilitating the 
investigation of disease-specific phenotypes in vitro (Stadtfeld and 
Hochedlinger, 2010). 
IPSC technology, used to create a disease model for PRRT2 mutations, 
has been recently applied in two studies. In the first work, iPSC lines were 
generated from epithelial cells in urine samples of single PKD patient with 
the same mutation reported in our study, a c.649dupC heterozygous 
mutation (Zhang et al., 2015). In this work, PKD-iPSCs did not show any 
significant changes in ion currents that underlie the excitability properties of 
neurons, i.e. NaV and KV conductances.  
In the second study, multiple PKD-iPSC lines from two familial PKD 
patients with two different nonsense mutations (c.487C>T and 
c.573dupT) were generated (Li et al., 2016). PKD-iPSCs exhibited defects 
in neural conversion via a step-wise neural induction method, with an 
extremely low efficiency in generating NPCs compared to control-iPSCs. 
In the present work, we obtained iPSC-derived functional mature neurons, 
exhibiting similar efficiency across genotypes. We demonstrated for the first 
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time that cells obtained from fibroblasts of two homozygous PRRT2 
patients presented a significant increase in JNa+ and firing activity. 
Conversely, the heterozygous siblings exhibited a phenotype that paralleled 
the mild form of the clinical manifestations (Liu et al., 2016), in accord to the 
previous results from Zhang et al. (2015). Moreover, homozygous iPSC-
derived neurons showed an altered intrinsic excitability rescued by the 
reintroduction of human WT form of PRRT2. This capacity of PRRT2 to 
restore JNa+ and firing activity to a level comparable to that of control, may 
suggest that PRRT2 would influence the functionality of the NaV channels. 
Interestingly, a recent electrophysiological study has shown that mutated 
forms of different NaV α-subunits cause an induction of an increased 
persistent Na+ current in neuronal and muscle disorders of excitability 
(Jarecki et al., 2010). This cellular phenotype of hyperexcitability of iPSC-
derived neurons is recapitulated in hippocampal primary neurons from the 
PRRT2-KO mouse that also display a marked hyperexcitability at both 
single cell and network levels. The excitability properties of neuronal cells 
depend on the integration of the excitatory and inhibitory inputs at the 
neuronal trigger zone called AIS. At this level distinct clusters of different 
subtypes of NaV channels generate the potential response producing APs. 
Interestingly, the distal part of the AIS of glutamatergic neurons, has an 
abundant expression of NaV1.6, while the proximal part has more NaV1.2, 
which are the same channel subtypes that were inhibited by PRRT2 when 
recombinantly expressed in HEK-293 cells. On the contrary, the NaV1.1 
subtype, which is not affected by PRRT2 under conditions, plays a major 
role in the AIS of GABA-ergic neurons (Ogiwara et al., 2007; Debanne et 
al., 2011; Catterall, 2014). This is an agreement with the results on PRRT2-
KO neurons, showing that PRRT2 may alter more glutamatergic than 
GABA-ergic synapses and indicate that the latter are not altered from the 
adaptive changes when PRRT2 is absent. 
Our data show that this selective negative modulation of NaV1.2 and NaV1.6 
mediated by PRRT2 is caused by changing in interfering with the total 
amount of channels in the plasma membrane as demonstrated by the 
increased voltage-activated Na+ conductance, and by the increase of 
cellular excitability when PRRT2 was absent. The mechanisms that 
underlie this effect may depend on disturbed trafficking in favor of 
internalization. Moreover, PRRT2 also modulates the biophysical properties 
of subtypes NaV1.2/NaV1.6 channels. The results indicate that the voltage-
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dependence of fast inactivation was shifted to more negative values and 
the recovery from inactivation was slowed-down in the presence of PRRT2 
decreasing the amount of NaV channels that can be activated under resting 
conditions. Altogether, the data of this work clearly show that PRRT2 alter 
the biophysical properties of NaV1.2/NaV1.6, leading to a less excitability of 
the neurons, but only when correctly expressed. PRRT2 negatively 
modulates NaV1.2/NaV1.6 by decreasing their abundance in the plasma 
membrane promoting their internalization.  
 
 
4.4. Possible physiological and pathophysiological role of 
PRRT2 in Paroxysmal Disorders 
 
In this study we have demonstrated that PRRT2 interacts with NaV 
channels that play a fundamental role in generation and conductance of 
action potentials (Mantegazza et al., 2012). This specific interaction 
between PRRT2 and NaV channels and its effect on neuronal excitability 
indicate that in a physiological conditions PRRT2 has an additional role 
which implements its effect in the regulation of neurotransmitter release 
(Valente et al., 2016a). The observed interactions of PRRT2 with 
NaV1.2/NaV1.6 channels, which are major regulators of the excitability of 
excitatory neurons, represent a plausible basis for the phenotype of 
PRRT2-linked disorders. Several considerations support the 
pathophysiological relevance of these findings. Firstly, the behavioral 
phenotype of the PRRT2-KO mouse (Michetti et al., 2017) closely 
resembles the paroxysmal phenotype of mice with mutations in voltage-
dependent channels (Becker et al., 2009). Secondly, several studies 
reported mutations in different NaV channels that cause a spectrum of 
epileptic and dyskinetic syndromes negative for PRRT2 mutations (Heron 
et al., 2002; Scalmani et al., 2006; Gardella et al., 2016). The co-
segregating heterozygous missense mutation (c.4447G>A) described in 
sixteen members of three families (Gardella et al., 2016) hits the 
inactivation gate of the NaV1.6 α-subunit, suggesting an impaired channel 
inactivation that is consistent with the here described effects of PRRT2 on 
the NaV1.6 channels. Moreover, affected individuals with PRRT2-related 
paroxysmal manifestations respond well to low doses of Na+ channel 
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blockers, such as carbamazepine or phenytoin (Chen et al., 2011). 
Furthermore, patients with the same PRRT2 mutations may present 
variable phenotypes, indicating a pleiotropy in clinical manifestations 
(Brueckner et al., 2014) and comorbid conditions (Ebrahimi-Fakahari et al., 
2015; Gardiner et al., 2015). This pleiotropy has been found also in different 
channelopathies (Dichgans et al., 2005), suggesting that the differential 
expression of Na+ channels subtypes modulate the broad phenotypic 
expression of PRRT2 mutations.  
 
 
5. CONCLUSIONS 
 
The study presented in this thesis demonstrates that the lack of PRRT2 
leads to neuronal hyperexcitability through the upregulation of NaV 
channels in homozygous PRRT2-KO human and mouse neurons. In 
PRRT2-KO animal model, chronic absence of PRRT2 markedly alters 
neuronal network dynamics, making it more excitable and instable. We 
observed the same altered intrinsic excitability in human neurons obtained 
from iPSCs of patients carrying the most common mutation of the PRRT2 
gene. Previous functional studies showed that PRRT2 is a gene with 
pleiotropic functions in the control of neuronal excitability and synaptic 
transmission. The research presented in this thesis reveals additional 
mechanistic insights on PRRT2 regulation on neuronal activity. The results 
show that PRRT2 operates as negative modulator of NaV1.2 and NaV1.6 
channels which are selectively expressed in excitatory neurons. Given the 
predominant paroxysmal character of pathologies depending of PRRT2 
mutations, the imbalance in excitatory and inhibitory activity by lack of 
negative modulation of NaV channels at excitatory neurons appears as the 
key pathogenetic mechanism. 
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6. MATERIALS AND METHODS 
 
 
6.1. Animals 
PRRT2-KO mice were generated by EUCOMM/KOMP using a targeting 
strategy based on the “knockout-first” allele (Michetti et al., 2017). Mutant 
animals in a C57BL/6N background were propagated as heterozygous 
colonies in the IIT SPF facility. Genotyping was performed by PCR as 
previously described (Michetti et al., 2017) to identify WT and KO embryos 
used in the experiments. All experiments were carried out in accordance 
with the guidelines established by the European Communities Council 
(Directive 2010/63/EU of March 4th, 2014) and were approved by the Italian 
Ministry of Health (authorization n. 73/2014-PR and n. 1276/2015-PR). 
 
 
6.2. Cell culture procedures 
 
Low-density hippocampal neurons: primary cultures of hippocampal 
neurons were prepared from WT and PRRT2-KO mice as previously 
described (Baldelli et al., 2007; Chiappalone et al., 2009) with slight 
modifications. Animals were sacrificed by CO2 inhalation, and 17/18-day 
embryos (E17-18) were removed immediately by cesarean section. In brief, 
hippocampi or cerebral cortices were dissociated by enzymatic digestion in 
0.125% trypsin for 20 min at 37 °C and then triturated with a fire-polished 
Pasteur pipette. No antimitotic drugs were added to prevent glia 
proliferation.  
Autaptic hippocampal neurons: Primary cultures of hippocampal autapses 
were prepared as described previously (Valente et al. 2016b) with slight 
modifications. Dissociated neurons were plated at very low density (20 
cells/mm2) on microdots (40-300 μm in diameter) obtained by spraying a 
mixture of poly-L-lysine (0.1 mg/mL) and collagen (0.25 mg/mL) on Petri 
dishes or glass coverslip, previously pretreated with 0.15% agarose. Under 
this culture conditions, each coverslip showed about 10 isolated single 
autaptic neurons grown on polylysine microdots. Electrophysiological 
recordings were conducted on single and isolated autaptic neurons 
between 10 and 15 DIV. 
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HEK-293 cells: Stably expressing human NaV1.1, NaV1.2 or NaV1.6 HEK-
293 cell lines, were kind gifts from Drs. Enzo Wanke and Marzia Lecchi 
(University of Milano-Bicocca, Italy). HEK-293 cells were maintained in 
DMEM/F12 (1:1) Glutamax supplemented with 10% fetal bovine serum, 100 
units/ml penicillin, 100 μg/ml streptomycin and 500 μg/ml G418 for selection 
of NaV channels stably transfected cells. Cell lines were transfected 
according to manufacturer’s instructions at 80% confluency using 
Lipofectamine 2000. All reagents were purchased from Thermo Fisher 
Scientific. 
 
 
6.3. Generation and maintenance of iPSC lines 
 
IPSCs were generated from dermal fibroblasts obtained from skin biopsies 
of three siblings of a consanguineous family segregating the common 
PRRT2 mutation c.649dupC. Skin biopsies were performed upon informed 
consent at the Department of Medical Sciences, Institute of Neurology, 
University "Magna Graecia", Catanzaro, Italy, using the punch biopsy 
procedure and fibroblasts were cultured in RPMI (GIBCO) supplemented 
with 20% (v/v) FBS, 2 mM L-Glutamine and 1% Penicillin/Streptomycin. For 
control iPSC lines (FF0201992 and FF0631984), fibroblasts of age-
matched normal male donors were obtained from the “Cell Line and DNA 
Biobank from Patients affected by Genetic Diseases” (Institute Giannina 
Gaslini, Genova, Italy), that is member of the Telethon Network of Genetic 
Biobanks (project no. GTB12001).  
Cells at low passages (2-3) were reprogrammed using the Sendai virus 
non-integrated CytoTune™-iPS reprogramming Kit (Thermo Fisher 
Scientific) according to manufacturer's instructions. CytoTune™-iPS 
reprogramming Kit uses vectors based on a modified, non-transmissible 
form of Sendai virus to safely and effectively deliver and express key 
genetic factors necessary for reprogramming somatic cells into iPSCs. The 
reprogramming vectors include the four Yamanaka’s factors, OCT3/4, 
SOX2, KLF4, and C-MYC, shown to be sufficient for efficient 
reprogramming. 
Colonies appeared after 25 days. At least 20 single colonies for each 
genotype were isolated by manual picking, maintained on Geltrex-coated 
(Thermo Fisher Scientific) plates on a layer of mitotically inactivated murine 
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embryonic CF-1 fibroblasts (GlobalStem) in human ESC culture medium 
consisting of DMEM/F12 Glutamax supplemented with 20% knockout 
serum replacement, 1% non-essential AAs, 1% penicillin/streptomycin, 0.55 
mM β-mercaptoethanol and 10 ng/ml recombinant human fibroblast growth 
factor-2 (FGF-2) (all from Thermo Fisher Scientific). Cultures were fed daily 
and passaged using collagenase IV every 3-5 days. Each clones was 
expanded separately as cell lines, which are named in deidentified codes. 
At passage 15, clones were tested for pluripotency marker expression by 
qRT-PCR and immunofluorescence. For in vitro differentiation into cells of 
all three germ layers, confluent undifferentiated iPSC were incubated in 
1 mg/ ml collagenase IV (Thermo Fisher Scientific) for 1 h at 37 °C and 
transferred to 100 mm low attachment plates in EB medium (hESC without 
FGF2). 
 
 
6.4. Differentiation of iPSC clones into neurons  
 
For neuronal differentiation, embryoid bodies were generated from iPSCs 
clones, cultured for five days in suspension in embryoid body medium and 
then collected and plated into a Geltrex-coated 6-well plates for additional 
seven days to form neural tube-like rosettes. After seven days, the 
emerging neural rosettes were picked manually, completely dissociated 
with Accutase at 37°C for ten minutes and then transferred to Geltrex-
coated plates in NPC medium consisting of DMEM/F12 supplemented with 
N2 (1:100), B27 (1:500; GIBCO), epidermal growth factor (20 ng/ml) and 
FGF-2 (20 ng/ml). NPCs were expanded and fed every other day. To obtain 
terminally differentiated neurons, NPCs were infected with a lentiviral vector 
containing Green Fluorescent Protein (GFP)-expressing lentiviruses in co-
culture with E18 rat primary cortical neurons at seven DIV, previously 
infected with TdTomato-Lentivirus, in order to discriminate human cells 
from rat cells. The differentiation lasted 25-45 days in Neurobasal-A 
medium supplemented with 2mM L-glutamine, N2, B27, BDNF and GDNF 
and retinoic acid. For iPSCs, three germ layer cells and NPCs, staining was 
performed with PSC 4-MARKER ICC Kit, 3-GERM LAYER ICC Kit and 
NSC ICC Kit respectively (all from Thermo Fisher Scientific) according to 
manufacturer’s instructions. 
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6.5. Analysis of network activity of primary hippocampal 
cultures on MEAs 
 
Planar MultiElectrode Arrays (768-GL1-30Au200 from Axion BioSystems) 
were used to record the electrical activity of WT and PRRT2-KO primary 
hippocampal networks. MEA plates are composed of 12 wells, each 
containing an array of 64 nano-porous gold electrodes (30 µm electrode 
diameter; 200 µm center-to-center spacing). To enhance hydrophilicity, 
wells were treated overnight with poly-L-lysine (0.1 mg/ml, Sigma-Aldrich) 
in 100 mM borate buffer pH 8.5 and rinsed three times with sterile 
deionized water to remove the excess of poly-L-lysine. Afterwards, neurons 
were plated on MEAs at a density of 80,000 per well. Neuronal cultures 
were maintained in 1.5 ml cell culture medium (Neurobasal medium, 1% 
Glutamax, 2% B27, 1% Penicillin-streptomycin) and half-volume 
replacement of the medium was performed twice weekly, at least 24 h 
before the electrophysiological experiments. Spiking activity from 
hippocampal networks was recorded using the Axion BioSystems hardware 
(Maestro amplifier and Middle-man data acquisition interface) and software 
(Axion Integrated Studio, version 2.1). After 1,200 x amplification, raw data 
were digitized at 12.5 kHz/channel and stored on a hard disk for 
subsequent off-line analysis.  
Recordings were collected between the second and the third week in vitro 
from a total of 95 cultures (46 from PRRT2-KO and 49 for WT, four 
independent preparations). Spontaneous activity was recorded for 15 min 
at 37 °C under ambient atmospheric conditions, starting ten minutes after 
the transfer from the incubator to the Maestro apparatus to ensure 
stabilization of the electrical signal. On the last day of recording, the 
spontaneous activity was monitored for 20-30 min before applying low-
frequency electrical stimulation. One electrode of the array was chosen as 
stimulation site based on visual inspection of the evoked responses, to 
ensure maximal activation of the network. The stimulus pulse was biphasic 
(1.5 V peak-to-peak amplitude, 500 μs duration, 50% duty cycle) and was 
delivered at 0.2 Hz (Wagenaar et al., 2004). Only the electrodes recording 
spontaneous spiking activity was chosen as stimulation sites. After the 
stimulation session, BIC was directly added to the culture medium at the 
final concentration of 30 μM (Keefer and Gramowski 2001; Gramowski et 
al. 2004). After five minutes equilibration period, recordings were carried on 
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for further 20 min. A total number of 63 cultures (32 for WT and 31 for KO) 
from three independent preparations were treated with BIC.  
When stimulating currents/voltages are delivered through one electrode of 
the array at a constant frequency, the network responds by generating a 
rich repertoire of reverberating electrical activities, lasting 100-200 ms 
(Shahaf and Marom, 2001). To analyze the neuronal activity evoked by 
electrical stimulation, we represented the impulse response of each site of 
the experimental preparation by means of a post-stimulus time histogram 
(PSTH). We summated over time (5-ms bin) the spiking responses to the 
50 stimuli in the train over a 200-ms period after the stimulus to generate a 
cumulative histogram that was afterwards normalized by the total number of 
stimuli and the bin size (Rieke et al., 1997). Evoked activity was analyzed 
using Neuroexplorer (Nex Technologies). Only active channels (i.e., having 
a PSTH > 1 in the whole stimulation session) were considered for statistical 
analysis. 
 
 
6.6. Electrophysiological experiments 
 
Whole-cell patch-clamp recordings were made, as previously described 
(Baldelli et al. 2007; Valente et al. 2012). Patch pipettes, prepared from thin 
borosilicate glass (Hilgenberg) were pulled and fire polished to a final 
resistance of 2-4 M when filled with standard internal solution. Whole-cell 
currents were recorded using an EPC-10 amplifier (HEKA Electronic). 
Voltage-clamp recordings of voltage-gated Na+ currents and current-clamp 
recordings investigating single cell firing rates were acquired at 20 kHz and 
low-pass filtered at 4 kHz, while the AP shape was sampled at 50 kHz and 
low-pass filtered at 10 kHz. Recordings with leak currents >200 pA or 
series resistance >20 M were discarded. Data acquisition was performed 
using PatchMaster program (HEKA Elektronic). Series resistance was 
compensated 80% (2 s response time) and the compensation was 
readjusted before each stimulation. The shown potentials were not 
corrected for the measured liquid junction potential of 9 mV. All recordings 
were performed at 22-24 °C. The whole-cell patch-clamp recordings were 
performed on autaptic neurons grown on micro islands, on low-density 
primary neurons and on cultures of IPSCs, as previously described 
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(Valente et al., 2012). Measures were conducted on single and isolated 
autaptic cells between 10 and 15 DIV.  
Evoked excitatory and inhibitory postsynaptic currents (eEPSCs/eIPSCs) 
were recorded using an EPC-10 amplifier (HEKA Electronic). For whole-
cells recordings, cells were maintained in a standard external solution 
containing (in mM): 140 NaCl, 2 CaCl2, 1 MgCl2, 4 KCl, 10 glucose, 10 
HEPES (pH 7.3 with NaOH). To record eEPSCs, where otherwise not 
indicated, D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5; 50 M; 
Tocris) and bicuculline (BIC, 30 M, Tocris) were added to the Tyrode 
solution to block N-methyl-D-aspartate (NMDA) and GABAA receptors, 
respectively. To record eIPSCs, 6-cyano-7-nitroquinoxaline-2, 3-dione 
(CNQX; 10 M) and CGP 58845 (CGP; 10 M) were added to the external 
solution to block non-NMDA and GABAB receptors, respectively. The 
standard internal solution was (in mM): 126 KGluconate, 4 NaCl, 1 MgSO4, 
0.02 CaCl2, 0.1 BAPTA, 15 glucose, 5 HEPES, 3 ATP, 0.1 GTP (pH 7.2 
with KOH). For experiments in which eIPSCs were studied, the following 
internal solution was used (in mM): 140 KCl, 4 NaCl, 1 MgSO4, 0.1 EGTA, 
15 Glucose, 5 HEPES, 3 ATP, 0.1 GTP (pH 7.2 with KOH). Unclamped 
APs were evoked by a brief depolarization of the cell body to +40 mV for 
0.5 ms at 0.1 Hz using a Vh =-70 mV. Evoked PSCs were acquired at 10-20 
kHz sample frequency and filtered at 1/5 of the acquisition rate with an 8-
pole low-pass Bessel filter. Recordings with leak currents >100 pA or series 
resistance >20 M were discarded. Data acquisition was performed using 
PatchMaster programs (HEKA Elektronic). EPSCs were inspected visually, 
and only those that were not contaminated by spontaneous activity were 
considered. Macroscopic currents were elicited using a family of 
depolarizing 10 ms-voltage steps from -50 to 60 mV and a ramp protocol 
consisting of a voltage step of 200 ms from the holding potential to -100 mV 
followed by 100-ms linear ramp up to 120 mV. In both protocols cells were 
clamped at a Vh of -70 mV before stimulation. 
HEK-293 stably expressing human NaV1.1, NaV1.2 and NaV1.6 were 
transfected with 2 μg of PRRT2-HA plasmid or empty vector pKH3 (mock) 
with Lipofectamine 2000, following the manufacturer’s recommendations. 
To identify transfected cells, a co-transfection with a second plasmid 
containing the Tomato fluorescent protein reporter (Clontech) was done. 
Voltage-clamp recordings of voltage-gated Na+ currents were performed 
using the following Extracellular Solutions (in mM): 140 NaCl, 3 KCl, 1 
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MgCl2, 1 CaCl2, 10 HEPES, 10 Mannitol (pH 7.3 with NaOH); and as 
Intracellular (in mM): 140 CsCl, 10 NaCl, 2 EGTA, 10 HEPES (pH 7.3 with 
CsOH). Linear capacity and leakage currents of recordings were eliminated 
by P/N leak subtraction procedure. 
Whole-cell family currents of fast inactivating NaV channels were evoked by 
5 mV steps depolarization from -80 to 65 mV and cells were held at -120 
mV. Steady-state inactivation curves were constructed by recording the 
peak currents amplitude evoked by 20-ms test pulses to -10 mV after 500-
ms prepulses to potentials over the range of -130 to 10 mV. Time-
dependent rate of recovery from inactivation was calculated by prepulsing 
the cell with a 20-ms step to -20 mV to inactivate the channels and then 
bringing back the potential to -100 mV for increasing recovery durations 
(0.5, 1, 2, 4, 8, 32, 64, 128, 148 ms) before the test pulse of -20 mV. Linear 
capacity and leakage currents were eliminated by P/N leak subtraction 
procedure. 
 
 
6.7. Analysis of electrophysiological data 
 
Spontaneous and asynchronous release. Miniature excitatory (mEPSC) 
and inhibitory (mIPSC) postsynaptic currents were both collected from low-
density plated neurons incubated in the presence of tetrodotoxin (TTX, 1 
μM; Tocris) to block spontaneous APs. mEPSC were recorded in the 
presence of D-AP5 (50 M), CGP (10 M) and BIC (30 M), while mIPSC 
were recorded with D-AP5 (50 M), CGP (10 M) and CNQX (10 M) in the 
extracellular solution. mPSC analysis was performed using the Mini 
analysis program (Synaptosoft). The amplitude and frequency of mPSCs 
were calculated using a peak detector function with appropriate threshold 
amplitude and threshold area. The delayed asynchronous release of 
excitatory autapses was evoked by a tetanic stimulation lasting 2 s at 40 
Hz. Asynchronous release was estimated by measuring the charge (pA*ms) 
of the spontaneous PSCs that follow the stimulation train, in 9 consecutive 
time-windows lasting 1 s each. 
Short-term plasticity. In order to analyze the paired-pulse ratio (PPR), two 
brief depolarizing pulses were applied to autaptic neurons with variable 
interpulse intervals ranging from 20 to 10,000 ms. For each couple of 
PSCs, PPR was calculated as the I2/I1 ratio, where I1 and I2 are the 
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amplitudes of the PSCs evoked by the conditioning (1) and test (2) stimuli, 
respectively. To correctly evaluate the amplitude of I2, the baseline of I2 was 
defined as the final value of the decay phase of I1 and the amplitude of I2 
was calculated by subtracting the residual amplitude of I1 from the peak 
value of I2. In the analysis of synaptic responses during tetanic stimulation, 
the interpulse interval was shorter than the time needed for a PSC to return 
to baseline, so PSCs overlapped partially. Thus, to correctly estimate the 
PSC amplitude, the baseline of each event was calculated as the final value 
of the decay phase of the preceding ePSC and the amplitude of PSC (n) 
was calculated by subtracting the residual amplitude of PSC (n-1) from its 
peak value.  
Cumulative PSC amplitude analysis. The size of the RRP of synchronous 
release (RRPsyn) and the probability that any given SV in the RRP will be 
released (Pr) were calculated using the cumulative amplitude analysis 
(Schneggenburger et al., 2002). The cumulative amplitude plot was 
determined by summing up peak EPSC amplitudes during 40 repetitive 
stimuli applied at 40 Hz. This analysis considers that depression during the 
steady-state phase is limited by a constant recycling of SVs with an 
equilibrium existing between released and recycled SVs and that Pr during 
the train approaches the 1 value (Schneggenburger et al., 1999). The 
number of data points for the linear fitting of the steady-state phase was 
evaluated by calculating the best fit including the maximal number of data 
points starting from the last data point (i.e., from the 40th eEPSC). The 
cumulative amplitude profiles of the last 15-20 data points were fitted by 
linear regression and back-extrapolated to time 0. The intercept with the Y-
axis gave the RRPsyn and the ratio between the amplitude of the first PSC 
(I1) and the RRPsyn yielded the Pr.  
Analysis of firing activity. The rheobase was calculated as the minimum 
depolarizing current needed to elicit at least one action potential. Input 
resistance was recorded using the Ohm’s low in the linear region of the 
voltage-current relationship determined after injection of hyperpolarizing 
and depolarizing current steps (-10, -10, 10, 20 pA). For each recorded cell, 
the plot of the time derivative of voltage (dV/dt) versus voltage (phase-plane 
plot) was constructed from the first AP elicited by the minimal current 
injection. This plot was used to extract threshold potential, maximum rising 
slope and peak potential (V max). Amplitude of APs was calculated as the 
difference between the V max and the threshold value. 
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The instantaneous firing frequency and the mean firing frequency were 
determined at the minimal value of injected current able to evoked two or 
more APs. The instantaneous firing frequency was estimated as the 
reciprocal value of the time difference between the first two evoked APs. 
The mean firing frequency was calculated as the ratio of the number of APs 
evoked by the minimal current injection to the time interval (s) between the 
first and the last evoked action potential (Valente et al., 2016b). Firing 
activity was also studied using trains of 5 ms-steps applied at various 
frequencies (10-120 Hz). The current value used to evoke APs with this 
protocol was selected as the minimal current able to evoke an AP for each 
step of the train at 10 Hz (100% of probability) and increased by 100 pA. 
Analysis of Na+ currents. The current density (J) was obtained by dividing 
the peak current by the cell capacitance (nA/pF). The rheobase was 
calculated as the minimum depolarizing current needed to elicit at least one 
AP. Input resistance was calculated using the Ohm’s law in the linear 
region of the voltage-current relationship determined after injection of 
hyperpolarizing and depolarizing current steps (-10, -10, 10, 20 pA). For 
each recorded cell, the plot of the time derivative of voltage (dV/dt) versus 
time (phase-plane plot) was constructed from the first action potential 
elicited by the minimal current injection. This plot was used to extract 
threshold potential, maximum rising slope and peak potential (Vmax). 
Amplitude of action potentials was calculated as the difference between the 
Vmax and the threshold potential. The instantaneous firing frequency and the 
mean firing frequency were determined at the minimal value of injected 
current able to evoked two or more action potentials and is valued as 
previously described (Valente et al., 2016b). The conductance-voltage 
relationship curves were obtained by converting the maximal current 
values, evoked with the voltage step protocols, to conductance using the 
relation GNa = INa/(V-VR), where GNa is the Na+ conductance, INa is the peak 
Na+ current, V is the command pulse potential, and VR is the theoretical 
reversal potential of Na+ current. The normalized activation and inactivation 
curves for each cell were fitted to the Boltzmann equation in the form: 
Y=1/{1+exp[(V-V0.5)/k]}, where Y is the normalized GNa or INa, V the is the 
command pulse potential, V0.5 is the voltage required to activate the half-
maximal conductance or inactivation, and k is the slope of curve. The 
macroscopic currents, the shape of action potentials, firing activity and Na+ 
currents were analyzed using the pClamp software (Axon), PatchMaster 
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program (HEKA Elektronic), OriginPro 8 (OriginLab Corp.) and the Prism 
software (GraphPad Software, Inc.).  
 
 
6.8. Biochemical assays 
 
Pull-down and co-immunoprecipitation. HEK-293 cells stably expressing 
NaV1.1 or NaV1.2 or NaV1.6 subtypes were transfected with PRRT2-HA and 
BAP-HA as control; after 24 h cells were harvested in lysis buffer (1% Triton 
X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.4, with protease inhibitors 
cocktail). For pull-down assays, 20 μl of monoclonal anti-HA-Agarose 
affinity resin (Sigma-Aldrich) was incubated with cell extract according to 
manufacturer’s instructions for 2 h at 4 °C. After extensive washes in lysis 
buffer and detergent-free lysis buffer, samples were resolved by SDS-
PAGE and subjected to western blotting with polyclonal anti-HA and anti-
PanNaV antibodies. For immunoprecipitation, 5 μg of mouse anti-PanNaV or 
mouse control IgGs were precoated with Protein G Sepharose (GE 
Healthcare) overnight and incubated with a mouse membrane fraction in 
lysis buffer. After extensive washes in lysis buffer and detergent-free lysis 
buffer, samples were resolved by SDS-PAGE and subjected to western 
blotting with anti-PRRT2 and anti-PanNaV antibodies. 
Surface biotinylation. HEK-293 cells stably expressing NaV1.1 or NaV1.2 or 
NaV1.6 subtypes were transfected with PRRT2-HA plasmids or empty 
vector pKH3 as a control. Briefly, cells were incubated with 1 mg/ml of EZ-
Link™Sulfo-NHS-SS-Biotin in cold phosphate-buffered saline (PBS) for 40 
min at 4°C, constantly moving. Free biotin was quenched, twice, with 
100mM Tris in cold PBS, and once with cold PBS to remove biotin excess. 
The cells were then harvested with lysis buffer for 30 minutes. Whole-cell 
lysates were centrifuged at 16,000 x g at 4 °C for 15 min. 1 mg of the 
supernatant was incubated with 100 μl of NeutrAvidin conjugated agarose 
beads for 3 h at 4°C, and the remaining supernatant was kept as input. The 
beads were subsequently washed five times with lysis buffer before elution. 
All reagents were purchased from Thermo Fisher Scientific. 
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6.9. Immunofluorescence 
 
For iPSCs, three germ layer cells and NPCs, stainings were performed with 
PSC 4-MARKER ICC Kit, 3-GERM LAYER ICC Kit and NSC ICC Kit 
respectively (all from Thermo Fisher Scientific) according to manufacturer’s 
instructions. For iPSC-derived neurons, primary cortical neurons and HeLa 
cells, immunofluorescence was performed (see Corradi et al., 2014). 
PRRT2 staining was performed as described in Liu et al. (2016). All images 
were taken by a Leica TCS SP8 confocal microscope or by a Zeiss 
AxioImager M2 microscope and analyzed with ImageJ. 
 
 
6.10. qRT-PCR and Western blotting 
 
qRT-PCR was performed in a real-time thermal cycler (CFX-96, Bio-Rad) 
using SsoFast EvaGreen Supermix (Bio-Rad). Total mRNA was extracted 
with RNAeasy mini or micro kit (Qiagen) according to the manufacturer’s 
instructions, and reverse transcribed using the iScript cDNA Synthesis Kit 
(Bio-Rad). Relative expression was calculated using the 2-ΔΔCt method 
(Pfaffl, 2001) by normalizing data to the geometric mean of three 
housekeeping transcripts (GAPDH, PPIA, RPL13A) using the CFX 
Manager 3.0 software (Bio-Rad). For western blotting analysis, protein 
concentration of the samples was determined using the BCA or Bradford 
assay and equivalent amounts of protein were subjected to SDS-PAGE on 
polyacrylamide gels and blotted onto nitrocellulose membranes. Blotted 
membranes were blocked for 1 h in 5% milk in Tris-buffered saline (10 mM 
Tris, 150 mM NaCl, pH 8.0) plus 0.1% Triton X-100 and incubated 
overnight at 4°C with the appropriate primary antibody. Membranes were 
washed and incubated for 1 h at room temperature with peroxidase-
conjugated secondary antibodies. Bands were revealed with the ECL 
chemiluminescence detection system (Thermo Fisher Scientific). 
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6.11. Statistical Analysis  
 
Data are expressed as means ±sem for number of independently 
differentiated clones (n). The non-parametric Mann-Whitney’s U-test was 
used in order to compare two sample groups that were not normally 
distributed. To compare more than two normally distributed sample groups, 
one-way ANOVA, followed by post-hoc multiple comparison tests was 
used. Statistical analysis was performed using Prism (GraphPad Software, 
Inc.) software. 
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8. APPENDIX 
 
8.1. List of abbreviations and acronyms 
 
β-gal: β-galactosidase 
AA: Amino-acid 
AIS: Axon initial segment 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AP: Action potential 
BAP: Bacterial alkaline phosphatase 
BIC: Bicuculline 
BDNF: Brain derived neurotrophic factor 
BFIE: Benign familial infantile epilepsy 
CACNA1A: Calcium voltage-gated channel subunit α1 A  
CGP 35348: 3-Aminopropyl-diethoxymethyl phosphinic acid hidrate 
C-MYC: Proto-oncogene C-MYC 
CNQX: 6-cyano-7-nitroquinoxaline-2, 3-dione 
CaV: Voltage-gated calcium channels 
D-APV: D-2-amino-5-phosphonovaleric acid 
DIV: Days in vitro 
DSP: Dispanin 
E: Embryonic day 
EA: Episodic ataxia 
EAA: Excitatory amino acid 
EB: embryoid body 
ECAT: ES cell-associated transcript 
EEG: Electroencephalography 
eEPSC: Excitatory evoked post-synaptic current 
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eIPSC: Inhibitory evoked post-synaptic current  
ESC: Embryonic stem cell 
Fbxo15: F-box only protein 15 
FGF-2: Fibroblast growth factor-2 
GABA: γ-Aminobutyric acid 
GDNF: Glial cell-derived neurotrophic factor   
GFP: Green fluorescent protein 
G/Gmax-V: Normalized conductance-voltage curve 
GLUA1: Glutamate AMPA receptor subunit 1 
ICCA: Infantile convulsion and choreoathetosis 
ID: Intellectual disability 
IPSC: Induced-pluripotent stem cell 
ISI: Interstimulus interval 
JK+: K+ current density 
JNa+: Na+ current density 
KCNMA1: Potassium calcium-activated channel subfamily α1 M 
KCNA1: Potassium voltage-gated channel subfamily A member 1  
KCNQ2/3: Potassium voltage-gated channel subfamily Q member 2/3 
KLF4: Kruppel-like factor 4 
KO: Knock-out  
KV: Voltage-gated potassium channel 
LIF: Leukaemia inhibitory factor 
MAP2: Microtubule-Associated Protein 2 
MEF: Mouse embryonic fibroblast 
MiRNA: Micro RNA 
mEPSC: Miniature postsynaptic current 
mIPSC: Miniature postsynaptic current 
MR-1: Myofibrillogenesis regulator 1 
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MRI: Magnetic resonance imaging 
NaV: Voltage-gated sodium channel 
NeuN: Neuronal nuclei 
NPC: Neural progenitor cell 
OCT3/4: Octamer-binding transcription factor ¾ 
P: Post-natal day 
PBS: Phosphate-buffered saline 
PD: Paroxysmal dyskinesia 
PED: Paroxysmal exercise-induced dyskinesia 
PHD: Paroxysmal hypnogenic dyskinesia 
PKD: Paroxysmal kinesigenic dyskinesia 
PNKD: Paroxysmal non-kinesigenic dyskinesia 
PPR: Paired-pulse ratio 
PR: Probability of release 
PRRT2: Proline-rich transmembrane protein 2 
PSC: Post-synaptic current 
PSD95: Post-synaptic density 95 kDa 
RRP: Readily releasable pool 
RRPsyn: Readily releasable pool of synchronous release 
SCN1A: Sodium voltage-gated channel α subunit 1  
SLC2A1: Solute carrier family 2 facilitated glucose transporter member 1 
SNAP25: Synaptosomal-associated protein 25 kDa 
SNARE: Soluble N-ethylmaleimide-sensitive factor (NSF) attachment 
protein (SNAP) receptor  
SOX2: Sex determining region Y-box 2    
Syp1: Synaptophysin-1    
Syt 1/2: Synaptotagmin1/2                                           
SV: Synaptic vesicle 
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STP: Short-term plasticity 
TTX: Tetrodotoxin 
V0.5: Half-maximal potential  
VAMP-2: Vesicle-associated membrane protein 2 
VGLUT1: Vesicular glutamate transporter 1  
Vh: Holding potential  
WT:  Wild-type 
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